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Abstract  
 
Chronic inflammation is a well-known risk factor for the development of colonic 
tumorigenesis. In this study, we show that the immunoproteasome (iP) subunit LMP7 plays a 
crucial role in the progression of colitis-associated carcinogenesis (CAC). The activity and 
function of the iP complex has been extensively studied in the context of MHC class I-
coupled antigen presentation, inflammation and infectious diseases.  
Here we show that the absence of LMP7 exerts a protective effect, since the LMP7-
deficient mice fail to develop a full scale of carcinogenesis after CAC induction with 
AOM/DSS treatment. Our findings demonstrate that LMP7 deficiency results in reduced 
protein expression of pro-tumorigenic cytokines IL-6 and TNF-α in the colon after AOM/DSS 
treatment. Additionally, LMP7-deficient mice also exhibit significantly decreased mRNA 
levels of pro-tumorigenic chemokines CXCL1, CXCL2 and CXCL3, as well as cell adhesion 
molecule VCAM-1, thus highlighting the role of LMP7 in regulation of these pro-tumorigenic 
factors. The net result of the lack of pro-tumorigenic cytokines and chemokines is an impaired 
recruitment and subsequent activity of tumour-associated neutrophils (TANs) in the colonic 
lamina propria. Furthermore, we show that the absence or pharmacological inhibition of 
LMP7 and the consequent blockade of NF-κB, abrogated the production IL-17A, which 
possesses a potent carcinogenic activity in the gut.  
Moreover, in vivo administration of a selective LMP7 inhibitor „ONX-0914‟ during 
CAC induction reduced the tumour incidence in wild-type (WT) mice. Taken together, we 
identify the iP complex as a crucial mediator of inflammation-driven colon carcinogenesis 
and we also propose LMP7 as a potential therapeutic target for CAC to limit the ongoing 
tumorigenesis in inflammatory bowel disease (IBD) patients. 
  
V 
 
Zusammenfassung 
 
Chronische Entzündungen sind ein bekannter Risikofaktor für die Tumorentstehung im 
Kolon. In dieser Arbeit zeigen wir, dass die Immunoproteasom (iP)-Untereinheit LMP7 eine 
entscheidende Rolle für die Entwicklung der Colitis-assoziierten Karzinogenese (CAC) spielt. 
Die Aktivität und Funktion des iP-Komplexes wurde bereits im Kontext von MHC-Klasse-I-
vermittelter Antigenpräsentation, Entzündungen sowie Infektionskrankheiten ausführlich 
untersucht. 
Hier zeigen wir, dass die Abwesenheit von LMP7 einen protektiven Effekt ausübt, da 
LMP7-defiziente Mäuse nach Induktion einer CAC mit AOM/DSS keine vollständige 
Karzinogenese aufweisen. Unsere Ergebnisse belegen, dass die LMP7-Defizienz zu einer 
verminderten Proteinexpression der proinflammatorischen Zytokine IL-6 und TNF-α im 
Kolon nach AOM/DSS Behandlung führt. Zusätzlich weisen LMP7-defiziente Mäuse sowohl 
signifikant verringerte mRNA-Level der tumorfördernden Chemokine CXCL1, CXCL2 und 
CXCL3, als auch des Zelladhäsionsmoleküls VCAM-1 auf. Das Fehlen der krebsfördernden 
Zytokine und Chemokine führt zu einer beeinträchtigten Rekrutierung sowie verminderter 
Aktivität der Tumor-assoziierten neutrophilen Granulozyten in der Lamina propria des 
Kolons. Weiterhin zeigen wir, dass die Abwesenheit bzw. pharmakologische Inhibierung von 
LMP7, sowie die sich daraus ergebende NF-кB-Hemmung, die IL-17A-Produktion reduziert 
und somit zu einer potenten Antitumor-Wirksamkeit im Darm führt. Darüber hinaus 
verringert die in vivo Verabreichung des selektiven LMP7-Inhibitors „ONX-0914‟ während 
der CAC-Induktion die Tumorhäufigkeit in Wild-Typ-Mäusen.  
Zusammenfassend können wir den iP-Komplex als entscheidenden Mediator der 
Entzündungs-assoziierten Karzinogenese im Dickdarm identifizieren und schlagen LMP7 als 
potentielles therapeutisches Ziel für die CAC vor, um eine Tumorentstehung im Kolon bei 
Patienten mit chronisch-entzündlichen Darmerkrankungen zu verhindern. 
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1. Introduction 
 
 
1.1. Proteasomes: multicatalytic protease complexes 
 
Proteasomes are multicatalytic protease complexes that are found in all the three domains of 
life: prokaryotes, archaea and eukaryotes. Proteasomes are essential for survival in eukaryotes 
and their main function is to regulate cellular protein turnover and disposal of damaged 
proteins. In eukaryotes, apart from their housekeeping function of proteolysis, they are known 
to be involved in a variety of important cellular regulatory processes as well, e.g. cell cycle 
control, apoptosis, transcriptional regulation, protein translation, DNA repair and MHC class I 
antigen presentation (Baugh and Pilipenko 2004; Goldberg 2007; King et al. 1996). 
 
1.1.1. Ubiquitin-proteasome system (UPS): targeted protein 
degradation mechanism  
 
The ubiquitin-proteasome system (UPS) is an elaborate mechanism by which unwanted 
intracellular proteins are first targeted for degradation by the ubiquitination machinery and 
subsequently recognised, unfolded and proteolysed by the proteasome. In the second process 
of proteolysis, extracellular proteins are degraded by the lysosome (Vilchez, Saez, and Dillin 
2014). Damaged, misfolded and aggregated proteins, collectively called as defective 
ribosomal products (DRiPs), are efficiently scavenged by the proteasomes (Vilchez, Saez, and 
Dillin 2014; Krüger and Kloetzel 2012). The composition of cellular proteome constantly 
undergoes a change, in response to various external as well as internal signals or simply 
during cellular ageing process. As a consequence, many damaged proteins accumulate and 
there is a progressive decline in the functional ability of the cell to maintain an optimal 
proteostasis.  
The selective degradation by UPS is initiated by the conjugation of ubiquitin, a highly 
conserved 76 amino-acid long residue polypeptide, to the target substrate protein. Ubiquitin is 
covalently attached to target proteins and subsequently changes the stability, cellular 
localisation, or subsequent activity of the target substrate protein (Pickart and Eddins 2004). 
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Ubiquitination is a highly specific and an energy-dependent process, which is achieved 
through a sequential enzymatic operation involving three distinct classes of enzymes (Fig 1.).  
                         
    
Figure 1. The ubiquitin-proteasome system (UPS) of protein degradation. Protein degradation 
through the UPS is a tightly regulated process involving several steps. 1) In the first activation step of the 
cascade, the ubiquitin (Ub) is activated in an ATP-consuming reaction by the E1 ubiquitin-activating enzyme 2) 
In the second step called conjugation, the activated Ub is transferred to an E2 ubiquitin-conjugating enzyme 3) 
In the third ligation step, with the help of E3 ubiquitin-ligase, E2 catalyses the transfer of poly-ubiquitin onto the 
protein that is meant to be degraded. 4) In the fourth and the final step, the proteasome unfolds the 
polyubiquitinated substrate in an ATP-dependent manner, removes the Ub chain through a proteasome-
associated Ub-hydrolase activity. The unfolded substrate now enters the proteasome barrel where the protein is 
degraded by the -subunits of the core 20s proteasome. The Ub molecules are recycled and the peptides 
generated are utilised in the major histocompatibility class (MHC) I coupled antigen presentation. 
 
Firstly, the ubiquitin-activating enzyme (E1) activates the carboxyl-terminal glycine 
residue of ubiquitin by utilising an ATP molecule. This activated ubiquitin, is transferred, in a 
second step, to a cysteine residue of an ubiquitin-conjugating enzyme (E2). In the final and 
the third step, an ubiquitin ligase (E3) links activated ubiquitin from the E2 enzyme to a lysine 
residue of the target substrate protein. The same chronological steps are repeated which links 
additional molecules to the primary ubiquitin via internal lysine-48 (K48) and the result is the 
formation of an ubiquitin chain. After ubiquitination, the poly-ubiquitynated protein is 
recognised by 26S proteasomes by binding to UBA (ubiquitin-associated-domains) or UBL 
(ubiquitin-like) domains and subsequently degraded (Finley 2009). Apart from the K48-linked 
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poly-ubiqutination, which signals proteasomal degradation of targeted proteins, there also 
exists a K63-dependent assembly of ubiquitin molecules that is involved in other cellular 
processes but not in protein destruction (Krappmann and Scheidereit 2005).  
 
1.1.2. The proteasome: a proteolytic machine for protein disposal 
 
In contrast to reversible processes such as phosphorylation-dephosphorylation of proteins, the 
proteasomal degradation results in complete shutdown of protein function due to its 
irreversible proteolysis (Wolf and Hilt 2004). The cellular location of the proteasomes is 
cytoplasmic as well as nuclear (von Mikecz et al. 2008). The proteasome machinery 
comprises of a 20S core which is designed to degrade only unfolded substrates. The 20S core 
can be associated with two regulatory particles 1) the 19S cap/PA700 and 2) IFN--induced 
11S/PA28 (Fig 2.). The most abundant regulator of proteasomes is the 19S complex which is 
associated with the 20S complex to form the 26S proteasome. The 26S proteasome is 
constitutively expressed in most tissues. The proteasome regulator 19S cap recognises the 
substrates selectively and acts as a gate to the interior of the 20S core (Ebstein et al. 2012). 
The second regulatory particle, 11S, is IFN--induced and activates peptide hydrolysis by 
proteasome. Reversible binding of this regulator to the proteasome increases peptide 
hydrolysis (Dubiel et al. 1992). Notably, unlike 19S, 11S regulator is not an ATPase and does 
not bind to poly-ubiquitin chains, suggesting that it may direct the proteasome towards 
ubiquitin-independent proteolytic functions (Thrower et al. 2000).  
The core 20s proteasome is a cylindrical shaped structure which comprises of four 
seven-numbered rings. The outer ring contains alpha (subunits and the central two rings 
are composed of beta ( subunits. The catalytic function of the proteasome lies in the inner 
ring within the  subunits, while the  subunits are catalytically inert. The -subunits from 
eubacteria have evolved from possessing a broad range enzymatic activity to present-day 
eukaryotic  subunits which have three distinctive enzymatic activities. Out of the seven  
subunits, only three have proteolytically active sites - β1, β2, and β5. Each active site has 
preferential cleavage specificities; β1 cleaves after the C-terminal side of acidic residues, β2 
cleaves after tryptic residues, and β5 cleaves after hydrophobic residues. Hence, their 
specificities are labelled as caspase-like, trypsin-like and chymotrypsin-like activities, 
respectively (Finley 2009; Wolf and Hilt 2004). Furthermore, formation of the so-called 
hybrid proteasomes have been reported, which contain a 19S regulator and an IFN--induced 
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11S regulator at opposing sites of the 20S complex (Fig 2.). The hybrid proteasome may 
contribute to a more efficient substrate proteolysis of some substrates; probably the intact 
substrate proteins are recognised first by 19S and interact with 20S proteasome, whose 
cleavage ability is modified by the 11S complex (Tanahashi et al. 2000).  
                                       
 
Figure 2. Possible configurations of 20S core with 19S and 11S complexes. The 19S (PA700) 
regulatory cap can associate at one or both ends of the 20S proteasome core to form the 26S proteasome. The 
IFN-γ-induced 11S (PA28) regulatory complex can bind at the free end of a 19S-20S complex to form a hybrid 
proteasome, or it can associate with both ends of the 20S proteasome core. 
 
The function of the 26S proteasome is not just breaking down the protein into 
individual amino acids, but into a highly heterogeneous mixture of oligopeptides of various 
lengths. In mammals, these peptides (usually 8–11 residues long) are used to evoke the 
adaptive immunity. Peptides dock onto the major histocompatibility (MHC) class I molecule 
in the endoplasmic reticulum, after they are transported via the peptide specific TAP 
transporter. The peptide-MHC complex at cell surfaces is recognised by the cytotoxic T- 
lymphocytes specific for that epitope (Kloetzel 2004). Furthermore, 26S proteasomes as 
crucial mediators of protein degradation also play an important role in diverse cellular 
processes such as cell signalling, DNA repair, gene transcription, apoptosis and regulation of 
cell cycle (Baugh and Pilipenko 2004; Baumeister et al. 1998; Goldberg 2007; Coux, Tanaka, 
and Goldberg 1996). 
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1.2. Immunoproteasomes: a specialised subtype of the 
proteasomes 
 
1.2.1. Biogenesis of immunoproteasomes 
 
In mammals, in response to the inflammatory cytokines such as interferon-γ (IFN-γ) and 
tumour necrosis factor- (TNF-), the constitutively expressed catalytic β-subunits are 
replaced by highly homologous inducible β-counterparts known as immunosubunits, to 
generate immunoproteasomes (iPs) (Fig 3.) (Groettrup, Kirk, and Basler 2010). The iP was 
named owing to its function during inflammation and infection as antigenic peptide generator 
for MHC class I presentation (Angeles, Fung, and Luo 2012). The iP is mainly expressed in 
cells of the immune system such as T cells, B cells, monocytes, macrophages, dendritic cells, 
or medullary thymic epithelial cells (Kniepert and Groettrup 2014). iP biogenesis is transient 
and inducible and hence, iP has a much shorter half-life than constitutive proteasome (cP) 
which is a process ensuring a rapid removal of iPs from the cells when the inflammatory 
conditions cease to exist (Ebstein et al. 2013; Yewdell 2005).  
Immunosubunits β1i [also known as low molecular mass peptide 2 (LMP2); 
proteasome subunit beta 9 (PSMB9)], β2i [also known as multicatalytic endopeptidase 
complex-like 1 (MECL-1); PSMB10] and β5i [also known as LMP7; PSMB8] are 
preferentially incorporated during proteasome assembly to form the iP upon IFN- induction 
(Ebstein et al. 2012). β1i and  β5i are encoded by genes in the MHC class II locus and are 
adjacent to the genes encoding transporter associated with antigen processing (TAP1-2). 2i 
gene was found outside the MHC class II region (Groettrup, Kirk, and Basler 2010; Glynne et 
al. 1991). The immunosubunits have been shown to display differential cleavage preferences 
and efficiencies for proteins in order to change the antigenic peptide repertoire which can aid 
in facilitating an improved adaptive immune response (Eggers et al. 1995; Gaczynska et al. 
1994). β1i, β2i and β5i exhibit preferential substrate cleavage after acidic, basic and 
hydrophobic amino acid residues, respectively (Groettrup et al. 2001). iPs possess distinct 
proteolytic activities that generate a different spectrum of peptides compared to cPs which 
better suits MHC class I antigen presentation. The iP has enhanced chymotrypsin- and 
trypsin- like activities but reduced caspase-like activity which makes antigenic peptides with 
high affinity C-terminals to the MHC class I molecules. This, at the end, leads to improved 
cytotoxic T-lymphocyte function (Angeles, Fung, and Luo 2012). The assembly of cP and iP 
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is regulated by proteasome maturation protein (POMP), which is also transcriptionally 
regulated by IFN-γ (Heink et al. 2005; Ramos et al. 1998). Recently, it was suggested that 
POMP recruits the -subunits to the -ring. Moreover, POMP promotes coordinated 
proteasome formation at the endoplasmatic reticulum (ER) membranes (Fricke et al. 2007). 
Additionally, it mediates the assembly of - and -rings to form a 20S proteasome and is 
therefore essential for the maturation of proteasomes. POMP turnover is an indicator for the 
rate of proteasome neogenesis because after the completion of 26S assembly, POMP itself 
becomes the first proteasomal substrate (Heink et al. 2005; Ramos et al. 1998). Depending on 
the production and availability of the immunosubunits, proteasomes containing both, 
constitutive- and immunosubunits, which are called mixed-type of proteasomes, can be 
formed (Dahlmann 2016). 
                         
     
Figure 3. Biogenesis of immunoproteasome. The catalytic core of the 20S proteasome is comprised of two 
outer seven -rings and two inner seven -rings which assemble to form the constitutive proteasome. In the 
presence of pro-inflammatory cytokines such as IFN-, the synthesis of three catalytic β “immunosubunits” 
occurs which are incorporated into newly formed proteasomes instead of their constitutive catalytic counterparts 
to form the 20S immunoproteasome. 
  
Apart from their presence in the cells of immune system, iPs appear to be 
constitutively expressed in the ocular lens and brain. These tissues do not need to generate 
MHC class I peptide ligands and this aspect strongly suggests an alternative function for 
immunoproteasomes (Yewdell 2005). Furthermore, apart from the iPs, two tissue-specific 
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versions of the 20S proteasome have been discovered till date. Thymoproteasomes are 
exclusively expressed in cortical epithelial cells of the thymus where they play a crucial role 
in the positive selection of T lymphocytes. Spermatoproteasome are located only in the testes 
where they are required during spermatogenesis (Kniepert and Groettrup 2014). 
 
1.2.2. Use of lmp7/β5i knock-out mice to characterise functions of 
immunoproteasomes in various disease models  
 
In addition to its role in shaping the antigenic peptide repertoire presented by MHC class I 
molecules, the iP has other roles in regulating cellular functions such as regulation of 
transcription and signalling pathways (Baugh and Pilipenko 2004; Baumeister et al. 1998; 
Coux, Tanaka, and Goldberg 1996; King et al. 1996; Gaczynska et al. 1994). To characterise 
these roles, lmp7/5i knock-out mice are used in immunological studies, in order to examine 
the immunopathology behind many disorders and infections. It is highly relevant to use 
lmp7/5i knock-out mice, as LMP7 is crucial for efficient maturation of iPs. The formation of 
cP or iP is achieved by cooperative incorporation of corresponding catalytic subunits into the 
mature proteasome. This model is based on experiments in T2 cells, which carry a deletion in 
the MHC class II locus for lmp2 and lmp7 genes encoding for 1i and 5i, respectively. 
According to cooperative model for assembly of iPs the pro-sequence, but not the catalytic 
activity, of LMP7 is needed for efficient incorporation of LMP2 and MECL-1 into 20S core 
complex (De et al. 2003; Kingsbury, Griffin, and Colbert 2000). 
The first study done on lmp7
-/- 
mice revealed that in all the analysed cells, the MHC 
class I surface expression was reduced about 25-45% compared to WT mice without affecting 
the analysed T and B cells populations (Fehling et al. 1994). The work concluded that this 
reduction is caused by a lack of peptides suitable for MHC class I antigen presentation, thus 
demonstrating that the efficiency of peptide generation is altered and negatively impacted by 
the lack of LMP7 subunit. A similar conclusion was drawn with a novel study done in iP-
deficient animals which lacked all the three immunosubunits. The presentation of a majority 
of MHC class I epitopes was highly reduced and even the diversity of MHC class I presented 
peptides was almost 50% different when compared to the control mice (Kincaid et al. 2012). 
In infection models, such as Lymphocytic Choriomeningitis virus (LCMV) and Listeria 
monocytogenes, the lmp7
-/- 
mice were able to mount a cytotoxic CD8
+
 T cells response (Strehl 
et al. 2006) whereas in case of Toxoplasma gondii infection the LMP7 deficient animals were 
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highly susceptible (Nussbaum et al. 2005). Together, these studies highlight the role of iPs in 
disease pathology. Our research group and others have highlighted the significance of LMP7 
during colonic inflammation. lmp7
-/- 
mice developed highly attenuated colitis due to reduced 
expression of pro-inflammatory cytokines mediated by nuclear factor-B (NF-B) (Schmidt 
et al. 2010; Basler et al. 2010). Therefore, the use of iP deficient mice, such the lmp7
-/-
 mice, 
signifies a crucial role of iPs in MHC class I antigen presentation during inflammation and 
infection. It also underscores the importance of the role of iPs in regulating central signalling 
pathways such as NF-B. 
 
1.2.3. Immunomodulation of LMP7 subunit as a means to 
evaluate its role in several disorders 
 
In humans, dysregulation of the iP has been linked to various clinical disorders, including 
cancer, neurodegenerative disease, heart disease, aging, infection and  inflammatory bowel 
disease (IBD) (Angeles, Fung, and Luo 2012; Visekruna et al. 2006). Exhaustive efforts have 
been made in the recent decades to identify many proteasome inhibitors (PIs) that can be used 
as molecular probes to guide us through the complex network of proteasome biology.  
Two of the Food and Drug Administration (FDA)-approved PIs known as Bortezomib 
and Carfilzomib, are already in used as therapy to multiple myeloma patients (Miller et al. 
2013). In mice model of colitis, Bortezomib has been used to inhibit LMP7 activity and has 
been found to significantly attenuate experimental colitis (Schmidt et al. 2010). A more 
specific inhibitor called as ONX-0914 (formerly known as PR-957) was designed to target 
only LMP7 subunit of the iP. In mouse model of rheumatoid arthritis, ONX-0194 was used as 
treatment and the results reversed signs of the disease (Muchamuel et al. 2009). ONX-0914 
has been tested in the mouse model of colitis and it was reported that upon DSS colitis 
induction, ONX-0914-treated mice as compared to the inhibitor-untreated group attenuated 
the course of acute intestinal inflammation (Basler et al. 2010). 
PIs are known to have a biased activity against transformed cells. Many preclinical 
studies have shown that these inhibitors act preferentially on hyper-proliferating cells than 
quiescent cells (Voorhees and Orlowski 2006). As proteasomes are required for NF-B 
activation (Schmidt et al. 2010), PIs act to inhibit NF-B transcription factor: which in the 
context of inflammation acts as an anti-apoptotic and pro-inflammatory factor. It is also 
reported that stabilisation of tumour suppressor proteins such as p53 occurs in the presence of 
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PIs. Expression of the p53 protein is controlled mainly by Mdm-2, an important negative 
regulator of p53, which is E3 ubiqutin-ligase initiating p53 degradation via the proteasome 
(McConkey and Zhu 2008). Thus, immunomodulation of iPs serves as an important 
therapeutic tool in inflammatory and autoimmune disorders as well as in various types of 
cancers. 
 
 
1.3. Colorectal Cancer  
 
Colorectal cancer (CRC) is the third most common malignancy and one of the leading causes 
of cancer-related deaths (Tenesa and Dunlop 2009). CRC is a complex disease that develops 
as a result of both genetic and environmental risk factors. The pathogenesis of CRC is 
influenced by multiple factors including diet, lifestyle, chronic inflammation as well as 
hereditary genetic predisposition (Fearon and Vogelstein 1990). Familial studies estimate that 
30% of all CRC cases are an inherited form of the disease. Of these about 5% are thought to 
be due to well-characterized inherited mutations. These mutations can be somatic in nature for 
e.g. in genes of the Wnt/ß-Catenin signaling pathway. The others can be hereditary in nature 
as in patients with Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer 
[HNPCC]) or familial adenomatous polyposis (FAP) (Goel et al. 2011).  
Another major risk factor for development of CRC is the presence of long-standing 
inflammatory bowel disease (IBD) which manifests as either Crohn‟s disease (CD) or 
ulcerative colitis (UC). All these variable determinants lead to CRC by contributing to the 
primary initiation of neoplastic transformation of healthy epithelium and/or to the 
development towards more severe clinical stages of the illness (Colussi et al. 2013).  
 
 
1.4. Inflammatory Bowel Disease (IBD) 
 
The two major clinically defined types of IBD, CD and UC, are chronic remittent or 
progressive inflammatory syndromes that may affect the entire gastrointestinal tract and the 
colonic mucosa, respectively (Kaser, Zeissig, and Blumberg 2010). IBD is represented mainly 
by UC and CD but also includes an intermediate state between them (Strober, Fuss, and 
Mannon 2007). IBD results from a complex series of interactions between susceptibility 
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genes, the environment, and the immune system. CD can affect any part of the gastrointestinal 
tract and usually presents itself with fatigue, prolonged diarrhea with or without bleeding, 
abdominal pain, weight loss, and fever. UC classically involves the colon and presents with 
symptoms that are usually linked to rectal bleeding, frequent stools, mucous discharge from 
the rectum, tenesmus, and lower abdominal pain (Wallace et al. 2014). The exact etiology of 
IBD is still unknown, but is thought to be due to impaired integrity of intestinal barrier and 
subsequent hyper-reaction of mucosal immune system to normally harmless antigens from 
diet and commensal bacteria, whereby chronic inflammation arises from Th1/Th17-mediated 
immune responses in CD and Th2-driven immunity in UC (Francescone, Vivianty Houm, and 
Grivennikov 2015). 
  
1.4.1. Colitis-associated carcinogenesis (CAC) 
 
Mounting evidence supports the notion that chronic inflammation is an important risk factor 
for the development of cancer. Colitis-associated cancer (CAC) is a subset of colon cancer 
which is preceded by clinically detectable IBD (Grivennikov 2013).The purpose of 
inflammation is generally to induce a normal host response to tissue damage inflicted by 
infections or other foreign agents. The host inflammatory response for most pathogens 
provokes an acute inflammatory response, which is self-regulated and is self-limiting. 
Inadequate resolution of inflammation and sustained inflammatory responses initiates chronic 
state inflammation, which can eventually lead to tumorigenesis (Fig. 4) (Terzić et al. 2010; 
Garrett, Gordon, and Glimcher 2010; Grivennikov, Greten, and Karin 2010). 
This chronic inflammation contributes to tumour initiation, by constant secretion of 
pro-inflammatory cytokines such as IL-17A and TNF- and ultimately inducing DNA 
damage and chromosomal instability. It also promotes tumorigenesis, by enhancing tumour 
cell proliferation and resistance to apoptosis. Inflammation also supports angiogenesis and 
tissue remodeling, both of which contribute to tumour cell invasion and metastasis. Owing to 
these altered biochemical processes, dysregulated inflammation goes hand-in-hand with the 
tumorigenesis (Wu et al. 2014). 
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Figure 4. Development of colitis-associated cancer (CAC). There is an intimate link between 
inflammation and carcinogenesis.1) Chronic inflammation which ultimately leads to CAC is characterised by 
production of pro-inflammatory cytokines such as IL-17A, TNF- and IL-6. Excessive production of these 
cytokines leads to constant activation of transcriptional factors such as NF-B, STAT3 and -catenin which 
results in the formation of aberrant crypt foci (ACF) of the epithelial cells (ECs). 2) Persistent inflammation, in 
the presence of invading microbes from the lumen, facilitates tumour promotion by activating ECs proliferation 
and inhibiting ECs apoptosis which results in the formation of adenoma. 3) Mutations and genomic instability in 
oncogenes and tumour suppressor genes (APC, p53, K-ras) occur in ECs. 4) Finally, tumour progression is 
followed by tumour metastasis. 
 
 
1.5. Mediators involved in progression of CAC 
 
1.5.1. Proteasome-dependent activation of NF-κB pathway and its 
role in inflammation-driven carcinogenesis 
 
Nuclear factor-B (NF-B) is a family of inducible dimeric transcription factors which is 
composed by five members: p50/p105 (NF- B1), p52/p100 (NF-  B2), c-Rel, RelB and RelA 
(p65).  In unstimulated cells, NF-κB dimers are inactive in the cytosol. They are retained in a 
dormant state through interaction with the inhibitory IκB proteins, consisting of three subunits 
namely IB, IB and IB. Activation of this latent NF-κB is triggered by various stimuli, 
either via the classical (canonical) or the alternative (non-canonical) NF-κB pathways (Fig. 
5). The classical pathway activates RelA-p50 and c-Rel-p50 dimers, whereas the mobilisation 
of p52-RelB dimers occurs after the processing of p100-RelB dimers by alternative signalling. 
A multitude of extracellular signals converge on an IκB kinase (IKK) complex, which is 
comprised of two distinct catalytic subunits IKKα (IKK1) and IKKβ (IKK2) which interact  
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Figure 5. Classical and alternative NF-B pathway. Under resting conditions, NF-B dimers are bound 
to inhibitory IκB proteins. NF-κB signaling is divided into two types of pathways. 1) The classical pathway (left) 
is induced by TNFR1, IL-1R and TLR signaling. IB is phosphorylated in an IKK-dependent manner and 
degraded by the proteasome, which results in the nuclear translocation of RelA/c-Rel-p50 heterodimers. This 
pathway activates proteins which are inflammatory in nature namely, cytokines, chemokines and adhesion 
molecules. 2) The alternative pathway (right) is induced by some TNF family cytokines, such as CD40L, BAFF 
and lymphotoxin-β (LT-β). It involves IKK-mediated phosphorylation of NF-B2 (p100) associated with RelB. 
This leads to partial processing of NF-B2 (p100) mediated by the proteasome and the generation of 
transcriptionally active p52-RelB complexes which translocate to the nucleus. The genes activated by this 
pathway mainly encode for proteins which contribute to lymphoid organogenesis and growth. 
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with a regulatory protein called as IKKγ or NF-κB essential modulator (NEMO) and together 
they are needed for NF-κB activation downstream (Kanarek and Ben-Neriah 2012; Ben-
Neriah and Karin 2011; Karin 2006) 
In order to activate the classical pathway, many immune signals including antigens, 
Toll-like receptor (TLR) ligands, inflammatory cytokines such as TNF and IL-1β, ionising 
radiation and viruses, lead to the phosphorylation-dependent activation of IKKβ, which in 
turn phosphorylates IκB bound to NF-κB dimers. This step then initiates poly-ubiquitination 
and subsequent proteasome-mediated degradation of IκB. Activation of the classical NF-B 
pathway induces functional classes of genes whose products mainly are inflammatory 
mediators which are required for migration of inflammatory and phagocytic cells at the site of 
injury or infection. These products are cytokines like IL-6 and TNF-, chemokines such as 
CXCL1-3 and CCL2-4, enzymes such as iNOS and COX-2, and cell adhesion molecules such 
as VCAM-1, ICAM-1 and E-selectin (Bonizzi and Karin 2004). This pathway has a major 
role in the control of innate immunity and inflammation (Baud and Karin 2009). 
The second pathway called as the alternative NF-B signalling pathway is stimulated 
by a limited number of cytokines that belong to the TNF superfamily, for e.g., BAFF, 
lymphotoxin  and CD40 ligand. Activation of IKK homodimers results in the 
phosphorylation and proteasome-dependent processing of p100 to p52. Nuclear translocation 
of RelB–p52 occurs and induces expression of genes important in controlling the 
development and cellular organization. NF-B activity during inflammation-driven 
carcinogenesis can be either anti-tumorigenic or pro-tumorigenic. On the one hand, NF-B 
activation results in a high cytotoxic activity against tumour cells. This anti-tumorigenic 
activity plays an essential role in cancer immunosurveillance. On the other hand, unchecked 
constitutive activation of NF-B exerts pro-tumorigenic functions (Ben-Neriah and Karin 
2011). Due to the nature of genes which are induced by NF-B, its constitutive activation 
leads to upregulation of anti-apoptotic genes, inflammatory cytokines and chemokines as well 
as cell adhesion molecules. The end result of hyperactivation of these genes, is the excessive 
recruitment of leukocytes at the site of inflammation and the release of reactive oxygen 
species (ROS) which damage the DNA and thereby causing mutations. NF-B activity is also 
known to promote epithelial-mesenchymal transition (EMT), by upregulation matrix 
metalloproteases (MMPs), which degrade the extracellular matrix around the tumour cells 
allowing them to relocate to adjoining tissues and spread. Cross talk between NF-B with 
other signalling molecules also leads to induction of a chronic state of tumour inflammatory 
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environment. For e.g., NF-B and STAT3, cooperatively control genes which are responsible 
for cell cycle control. NF-B-induced IL-6 directly activates STAT3 expression. Thus, the 
proteasome-dependent NF-B activity is a central signalling step, which tightly regulates 
important cellular processes contributing to the development and maintenance of 
inflammatory and pro-tumorigenic responses (Hoesel and Schmid 2013). 
 
1.5.2. Inflammatory networks underlying progression towards 
inflammation-associated colon cancer 
1.5.2.1. Dichotomy of immune cells within tumour microenvironment 
A functional relationship between chronic inflammation and cancer development has been 
recognized for long time. In 1863, Rudolf Virchow observed that there is a leukocyte infiltrate 
in transformed tissues, which he interpreted as the crossroad between origin of cancer and 
sites of chronic inflammation (Vendramini-Costa and Carvalho 2012). Since tumour cells 
themselves are antigenic, a plethora of immune cells namely neutrophils, macrophages as well 
as T cells are deployed to the tumour site in solid cancers such as in colorectal cancer 
(Gajewski, Schreiber, and Fu 2013; Terzić et al. 2010). Cancer immunoediting is a process 
which comprises of three phases 1) elimination or immunosurveillance; where cancerous cells 
are recognised and destroyed 2) equilibrium; which is a subclinical phase in which the tumour 
persists but cannot expand due to efficient anti-tumor immunity and finally 3) escape; which 
occurs when the delicate balance between the immune response and the tumour shifts more 
towards tumour promotion (Jacobs et al. 2015). Many innate and adaptive immune cells 
actively take part in cancer immunoediting. On the other hand, an inflammatory environment 
consisting of immune and stroma cells can strongly promote cancer development by 
providing newly emerging tumours with factors which are needed for growth, angiogenesis 
and metastasis (Coussens and Werb 2002). 
 
Innate immune cells in CAC 
The main purpose of the innate immunity is to elicit an immediate defensive response at the 
site of inflammation or infection. Coordination between gut epithelial barrier, tissue-resident 
and circulating leukocytes; namely phagocytic macrophages and neutrophils, dendritic cells 
(DCs), natural killer (NK) cells and innate lymphoid cells (ILCs) constitute a functional 
mucosal innate immunity (Lin and Karin 2007; Spits et al. 2013). Innate immune cells are 
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able to recognise foreign antigens through receptors that recognise pathogen-associated 
molecular pattern (PAMPs) and damage-associated molecular pattern (DAMPs) molecules, 
such as bacterial cell wall components and nucleic acids. Several families of mammalian 
pattern recognition receptors (PRRs) that recognize PAMPs have been identified including 
Toll like receptors (TLRs), nucleotide-binding oligomerization domain-like (NOD-like) 
receptors (NLRs), C-type lectin receptors (CLRs), and triggering receptors expressed on 
myeloid cells (TREMs) (Akira et al. 2006; Takeuchi and Akira 2010). Once the innate cells 
are activated, they stimulate the differentiation and proliferation of naïve T cells, through 
production of various regulatory cytokines for e.g. IL-6, IL-12, and IL-23. Since the innate 
cells produce inflammatory mediators such as cytokines and chemokine, they are also 
associated with an increased cancer risk and tumorigenesis (Fig. 6) (Elinav et al. 2013). 
Innate immune cells, such as neutrophils, are usually short-lived responder cell 
population, which are the first to reach the site of inflammation or infection. During chronic 
inflammation, when activated neutrophils persist and infiltrate tumours, they are known as 
tumour-associated neutrophils (TANs). TANs have been proposed to be one of the key 
mediators of malignant transformation and tumour progression (Mantovani et al., 2011). 
TANs can have two phenotypes anti-tumorigenic (N1) as opposed to pro-tumorigenic (N2) 
phenotype. The presence or absence of TGF-β defines the TAN phenotype and skews their 
differentiation toward the N2 pro-tumorigenic phenotype (Fridlender et al. 2009). Before they 
are deployed at the site of gut inflammation, the chemokine receptor CXCR4 expressed on 
neutrophils retain them in bone marrow, whereas the chemokine receptor CXCR2 and 
hematopoietic cytokine granulocyte colony-stimulating factor (G-CSF) allows their egress 
into the blood circulation. During neutrophil mobilisation, CXCR1 and 2 receptors located on 
neutrophils interacts with chemokines expressed by tumour cells themselves such as CXCL1-
3. In order to migrate from peripheral blood into the target tissue, neutrophils transmigrate 
through the endothelium, by physically engaging with the endothelial cell adhesion molecules 
such as ICAM-1 and VCAM-1. TANs are also a source of pro-tumorigenic cytokines such as 
LIL-17A and IL-1(Powell and Huttenlocher 2016; Shang et al. 2012). After reaching the gut 
during ongoing colonic inflammation, TANs can also amplify the tumorigenesis, through 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), which lead to DNA 
damage and genetic instability as seen in chemically induced carcinogenesis models such as 
the AOM/DSS model of carcinogenesis (Coffelt et al. 2015). It has been reported that 
infiltrating neutrophils in the colon are the source of IL-1 which enhances the NF-B/IL-6 
axis to promote CAC progression (Wang et al. 2014). Cytokines like TNF-also contribute 
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to the recruitment or persistence of TANs within the tumour microenvironment. The cytokine 
IL-17A, produced by +T cells, enhances neutrophil recruitment and promotes tumour 
growth along with metastasis (Mills 2008; Martin et al. 2009). 
Macrophages, like neutrophils, can also assume a range of different phenotypes based 
on the existing environmental stimuli. The classically activated type I or M1 macrophages, are 
efficient immune effector cells, which are able to kill microorganisms and tumour cells, 
present antigen, and produce high levels of immuno-stimulatory cytokines for T cell 
proliferation. The M2 phenotype or the tumour-associated macrophages (TAMs), on the other 
hand, is associated with tissue remodelling and angiogenesis. In tumours, when monocytes - 
the precursors of mature macrophages, are exposed to tumour-derived anti-inflammatory 
molecules like IL-4, IL-10, TGF-β1 and prostaglandin E2, they are known to develop into 
polarised or M2 macrophages. TAMs have poor antigen presenting ability and produce 
cellular factors that suppress T-cell proliferation and activity (Siveen and Kuttan 2009). 
TAMs express a variety of pro-angiogenic factors, such as vascular endothelial growth factor 
(VEGFA), epidermal growth factor (EGF) and CXCL8, which support angiogenesis. TAMs 
also release inflammatory mediators, such as reactive nitrogen intermediates, TNF-, IL-6, 
and IL-1β, which mediate DNA damage, oncogenic transformation and survival of 
transformed cells leading to inflammation-driven carcinogenesis (Biswas, Allavena, and 
Mantovani 2013). Collectively, innate cells such as TANs and TAMs are crucial factors, 
which contribute to the persistence of inflammation and act as a constant source of pro-
tumorigenic cytokines needed for activation and proliferation of epithelial cells. 
 
Adaptive immune cells in CAC 
Dominant mucosal effector T cell responses are provided by Th1 and Th17 subset of CD4
+
 T 
cells. A very tight regulation of these effector cells is required in order to maintain mucosal 
homeostasis. Animal studies have shown that loss of this regulation, by either excessive or 
dysregulated effector response, may perpetuate intestinal inflammation (Fig. 6).  
A subset of T helper cells called as Th17 cells, are abundant at the mucosal interfaces 
(Weaver et al. 2007). Th17 produce the cytokines IL-17A-F which are factors involved in 
increase in neutrophils (neutrophilia), tissue remodelling, and production of antimicrobial 
proteins. The differentiation of IL-17-secreting Th17 cells requires the expression of the 
transcription factor retinoic orphan receptor-t (ROR-t). The activation of ROR-t depends 
on signal transducers and activators of transcription-3 (STAT-3), which in turn is activated by 
17 
 
IL-6, IL-21, and IL-23 (Ivanov et al. 2009; Ivanov et al. 2006; Korn et al. 2009). More 
recently, Th17 cells have been implicated as central players in a plethora of autoimmune 
diseases in mice and humans such as EAE and colitis (Littman and Rudensky 2010). Apart 
from ROR-t and STAT-3, interferon-regulatory factor 4 (IRF4) was found to be essential for 
the development for the generation of Th17 cells during EAE (Brüstle et al. 2007). 
Furthermore, IRF4 levels were found to be increased in IBD patients and correlated with 
enhanced production of il-17 mRNA (Mudter et al. 2011; Mudter et al. 2008). Th17 cells have 
been found in human colon cancers (Su et al. 2010; Kryczek et al. 2009). Recent studies have 
shown that the inflammatory microenvironment promotes production of CCL20, which 
preferentially recruits CCR6-expressing Th17 cells in chronic inflammatory diseases such as 
IBD. Tumour cells, as well as tumour-derived fibroblasts, secrete MCP-1/CCL2 and 
RANTES/CCL5, both of which strongly attract Th17 cell migration to the site of colonic 
inflammation (Ye, Livergood, and Peng 2013). Therefore, accumulating evidence suggests a 
close association of Th17 cells with tumorigenesis. 
CD4
+
 T cells expressing CD25 and their master transcription factor fork head protein 
3 (Foxp3), are called as regulatory T cells (Tregs). Tregs have been dichotomised into two 
groups: natural tregs (nTregs), which arise from the thymus and then migrate to the periphery 
and inducible tregs (iTregs), which are generated by extrathymic induction from naïve T cells. 
The critical function of these cells, is to inhibit immune cells against self-antigens, thereby 
limiting autoimmunity and inflammation under physiological conditions (Beyer and Schultze 
2006). Tregs cells play also a role in suppressing immune function and promoting 
tumorigenesis. The role of Tregs in carcinoma is just beginning to emerge. A study has 
reported the presence of intra-tumoural T cells that co-express Foxp3 and ROR-t, in colon 
cancer and Crohn‟s disease pathogenesis. These cells that share features of both Treg and 
Th17 cells, accumulate in a stage-dependent manner in colon cancer in humans, and promote 
polyposis in mice. At inflamed mucosal sites, TGF-in combination with IL-6 and IL-1can 
facilitate high levels of ROR-t expression in newly generated Treg cells (Blatner et al. 2012). 
Intra-tumoural Tregs, which express CCR4/10/5 and CXCR4, arrive at the tumour site due to 
the presence of corresponding chemokines which attract them and hence, further contribute to 
tumorigenesis (Bos and Rudensky 2012). The expression of Foxp3 has been associated with a 
poor prognosis in several types of cancer, and Tregs have been shown to reduce the host anti-
tumor immune response mediated by CD8+ T cells, which highlights the role of Tregs in 
colon carcinogenesis (Becker, Fantini, and Neurath 2006).   
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A central role during cancer immune surveillance has been attributed to cytotoxic 
CD8
+ 
T cells. Adaptive immunity, mediated by conventional CD8
+ 
T cells, depends on the 
expression of MHC class I on the cell surface of targeted cells. Apart from viral, bacterial and 
self-antigens, MHC I molecules can also present mutant tumour neoantigens (Rock and Shen 
2005; Lu and Robbins 2015). After the presentation of tumour-specific antigens by antigen 
presenting cells such as dendritic cells, CD8
+ 
T cells become activated and release various 
effector proteins including IFN-γ, perforin, granzyme A, granzyme B, TNF-related apoptosis-
inducing ligand, and Fas ligand, which can induce apoptosis of tumour cells (Dunn, Old, and 
Schreiber 2004) . However, CD8
+ 
T cells have not only been implicated in cancer 
immunosurveillance but also in the immunopathogenesis of IBD. In the intestinal mucosa of 
active IBD patients, increased infiltration with CD8
+
 T cells, elevated expression of perforin 
and granzyme A has been found (Müller et al. 1998). Moreover, the expression of perforin 
has been correlated to tissue damage in UC patients (Souza et al. 2005). This tissue damage 
might be a direct consequence of CD8
+
 T cells cell-mediated destruction of colonic epithelial 
cells (Okazaki et al. 1993). Although high infiltrates with CD8
+
 T cells correlated with 
absence of pathological signs of early metastatic invasion and an improved survival rate in 
CRC patients (Pagès 2007; Fridman et al. 2012) , the role of CD8
+
 T cells in CAC seems to be 
not only anti-tumorigenic. On the one hand, CD8
+
 T cells controls tumour growth through 
immune surveillance, on the other hand, these cells contribute to intestinal inflammation and 
thereby might promote tumour growth (Waldner and Neurath 2009).  
 
1.5.2.2. Contribution of pro-inflammatory cytokines to carcinogenesis 
 
Cytokines are key signalling molecules which are secreted either by epithelial, immune or 
stromal cells, in response to injuries, infections or inflammation. Their primary role is to 
minimise the inflicted damage and support tissue repair. However, in chronic diseases such as 
in IBD, persistent productions of cytokines, such as TNF-, IL-17A and IL-6 contribute 
towards tumour formation and colitis-associated cancer progression (Fig. 6) (Vendramini-
Costa and Carvalho 2012).TNF- is released initially by activated macrophages and then by 
Th1 cells in response to pathogenic stimuli. TNF- produces multiple effects, including 
altered cell proliferation and cell death through distinct signaling cascades resulting from 
binding to TNFR type-I (TNFR1) and type-II (TNFR2). In general, TNFR1-mediated 
pathways result in cell death, altered target gene transcription, and cytokine production, 
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whereas activation of TNFR2 has an anti-apoptotic effect, acting through NF-κB pathway. 
TNF- also increases vascular permeability, leading to the recruitment of activated leukocytes 
to the site of infection or injury.  These properties make TNF- a promoter of inflammation, 
angiogenesis, and tumour dissemination; therefore, it is considered a tumour-promoting 
factor. It can act at different stages of carcinogenesis by inducing cellular transformation, 
hyperproliferation and tumour growth (Lu, Ouyang, and Huang 2006). It was recently 
reported that TNFRI ablation resulted in reduced tumour load upon CAC induction in mice 
(Popivanova 2008). It was also observed that TNFR2 along with TNFR2-induced NF-B 
activity was upregulated in epithelial cells upon CAC induction (Onizawa et al. 2009) . 
IL-6 is produced by cell types such as monocytes and macrophages, after being 
exposed to specific microbial molecules such as PAMPS during an inflammatory response. 
During late stages of carcinogenesis, IL-6 is also secreted by CD4
+ 
T cells (Bromberg and 
Wang 2009; Becker et al. 2004). IL-6 is an important cytokine which plays a role in the 
context of acute and chronic colonic inflammation. It was observed that IL-6 expression is 
significantly increased in IBD murine models of colitis, and that the blocking of IL-6 
signaling significantly inhibits the severity of colitis in mice (Grivennikov et al. 2009). IL-6 
expression is mainly regulated by NF-κB activation, and IL-6 acts on both colonic epithelial 
cells and immune cells. The interaction of IL-6 with IL-6 receptor, initiates the signal 
transduction cascades through transcription factors, Janus kinases (JAKs) and STATs which 
promotes cell-survival and cell-cycle progression of premalignant as well as cancer cells, by 
ultimately inducing th expression of anti-apoptotic genes (e.g., Bcl2, Bcl-xL) and cell 
proliferation-associated genes (e.g., c-Myc, Cyclin D1). In addition, IL-6 in combination with 
TGF-β, enhances the differentiation of Th17 cells. In the colonic lamina propria, IL-6 
produced by myeloid cells protects premalignant intestinal epithelial cells (IECs) from 
apoptosis (Grivennikov et al. 2009). Therefore, IL-6 trans-signaling leading to STAT3 and 
NF-B activation, is a potential and attractive therapeutic target for CAC progression 
(Waldner, Foersch, and Neurath 2012; Mizoguchi, Kanneganti, and Mino-Kenudson 2011).  
IL-17A is a pro-inflammatory mediator of a subset of CD4
+
 T cells namely Th17 cells. 
Majority of IL-17A is produced by them, although other immune cells also contribute to the 
pool of IL-17A namely neutrophils, ILCs and T cells (Mills 2008; Yazdani et al. 2015; 
Walker, Barlow, and McKenzie 2013). The IL-23/Th17 axis is one of the most prominent 
pathways contributing to IBD. IL-23 is instrumental for stabilizing the „Th17 signature‟, 
which includes secretion of IL-17A, and expression of ROR-t and IL-23R (Grivennikov et 
al. 2012; Hyun et al. 2012). IL-17A and IL-17F are best understood cytokines out of all the 
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six known IL-17 cytokines (IL17A-F). IL-17A and IL-17F bind as ligand homo- or 
heterodimers to dimeric IL-17RA-IL-17RC receptor complexes, to induce host defense 
responses against bacterial pathogens at epithelial and mucosal barriers of the skin, lung, and 
the colon (Gaffen 2009). In the colonic epithelial cells, IL-17A promotes the expression of 
antimicrobial peptides and facilitates host defense against infections. Many studies suggest 
that the pro-inflammatory cytokine IL-17A and IL-17-induced IL-1 and TNF- from 
macrophages play a role in activating neutrophil-specific chemokines, thereby recruiting 
neutrophils to the site of inflammation. Thus, IL-17A is an important inflammatory cytokine 
which links innate and adaptive immunity. In CAC, the majority of studies consider that IL-
17A acts as a promoter in tumour initiation and progression. The transcription factor NF-B 
has been identified as a molecular bridge between inflammation and cancer. IL-17A itself can 
further stimulate NF-B to induce its own expression in tumour cells, thereby creating a 
persistent chronic inflammatory state within the tumour microenvironment. Furthermore, IL-
17-mediated IL-6 expression is regulated primarily by NF-B and this IL-6 can further 
amplify the NF-B/IL-6 loop to establish a sustained inflammatory condition (Gaffen 2008; 
Moseley et al. 2003). The mechanism of IL-17A tumour promotion is also attributed to 
enhancement of tumour progression through angiogenesis. IL-17 induces fibroblasts and 
tumour cells to produce a variety of angiogenic factors, including PGE1, PGE2 and VEGF 
which promotes angiogenesis in the tumour. In CAC model, inflammatory cytokines 
including IL-6 and TNF- are markedly decreased in IL-17A deficient mice compared with 
WT animals, suggesting that IL-7A plays a pivotal role in promoting initiation of colitis-
associated cancer (Hyun et al. 2012). 
 
1.5.2.3. Role of pro-inflammatory chemokines in carcinogenesis 
 
Chemokines have emerged as essential immune mediators in the pathogenesis of IBD and 
CRC (Chow and Luster 2014). Chemokines are chemotactic factors that determine the 
migration and positioning of immune cells during inflammatory reactions. Chemokines are 
divided into four subfamilies based on the position of the first two N- terminal cysteine 
residues which includes the CC, CXC, CX3C, and XC subfamilies (Balkwill F. R. 2012). 
They act in a specific and coordinated manner by homing various subsets of immune cells to 
their anatomical destinations during homeostasis and also during inflammation (Balkwill F. 
2004). Directed migration of immune cells that express the appropriate chemokine receptor is 
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known to occur along a gradient of the corresponding ligand allowing cells to move towards 
high local concentrations of chemokines at the site of inflammation. Increased expression and 
production of chemokines by epithelial cells in the damaged mucosal barrier allow the 
specific trafficking of leukocytes and lymphocytes of both the innate and adaptive immune 
response to the gastrointestinal mucosa (Richmond 2002).  
 
      
Figure 6. Inflammation-associated carcinogenesis. Cytokines secreted by inflammatory immune cells 
and tumour can either promote tumour development and tumour cell survival or exert anti-tumour effects. The 
CD8+ T cells act with their tumour suppressive capacity and try to inhibit tumour progression. When 
dysregulated chronic inflammation prevails and disturbs the existing immune equilibrium status, pro-
tumorigenic environment develops through the action of various inflammatory mediators, including TNF-α, IL-
6, and IL-17A. This ultimately leads to eradication of anti-tumour immunity and accelerated tumour progression. 
 
During ongoing inflammation, chemokine production in the tissue occurs in response 
to pro-inflammatory cytokines, such as TNF- and IL-1 that are released by local immune 
cells for e.g., activated neutrophils, DCs, and macrophages. In parallel, these pro-
inflammatory cytokines can influence chemokine production and expression by local 
endothelial cells as well (Kakinuma and Hwang 2006). Dysregulated expression of 
chemokines and their corresponding receptors is implicated in a broad range of human 
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cancers such as colon cancer (Fig. 6) (Richmond 2002). Infiltrating leukocytes are not the 
only subset of cells that react to chemokine gradients in cancers; it has been observed that 
cancer cells themselves can express several chemokine receptors and respond to the existing 
chemokine gradients in the inflamed area (Philip 2001).  
The accumulation of leukocytes in solid tumours, such as colon cancer, is directly 
proportional to local production of chemokines by tumour and stromal cells (Balkwill F. 
2003).  CXCR4-CXCL12 is the most commonly found chemokine-chemokine receptor pair 
associated with malignant cancer cells. Other frequently encountered chemokines responsible 
for cancer spread are a multitude of inflammatory chemokines, such as the growth-related 
(GRO) family chemokines; CXCL1 (GRO-mouse KC), CXCL2 (GRO-/mouse MIP2), 
CXCL3 (GRO-) and their corresponding chemokine receptors, namely CXCR1-3. Studies 
have reported, that they are found to be upregulated in IBD patients and are likely to regulate 
immune cell trafficking in the IBDs (Turner et al. 2014; Dietrich et al. 2010). The GRO 
family chemokines act in an autocrine manner which supports the colonic tumour growth, 
survival, angiogenesis and finally metastasis (Dwinell, Johanesen, and Smith 2003) . Several 
chemokines are known to be mainly regulated by the transcription factor NF-B. They exhibit 
dysregulated expression patterns in IBD as well as colorectal carcinoma patients for e.g., 
CXCL8, a chemokine known to be upregulated in colitis and carcinoma, acts through CXCR1 
and this interaction has been linked to the epithelial-mesenchymal transition in colonic 
carcinoma (Dietrich et al. 2010). Therefore, studying the genetic, epigenetic, and 
immunological mechanisms which influence the expression of chemokines and chemokine 
receptors will help in understanding the underlying roles for those molecules in the 
progression of inflammation-induced neoplasia. 
 
1.5.2.4.  Intestinal epithelial cells: genesis of colorectal cancer 
 
The gastrointestinal tract constitutes a physical and biochemical barrier surface for the body. 
The intestinal epithelium is the largest of the body‟s mucosal surfaces. The gut epithelium has 
evolved to regulate water and nutrient absorption, carry out gaseous exchange as well as the 
keep the luminal contents and the mucosal immune cells segregated (Blanpain, Horsley, and 
Fuchs 2007). A single layer of intestinal epithelial cells (IECs) is organised into crypts and 
villi. This layer is continuously renewed at the base of the crypts, where the pluripotent 
intestinal stem cells (IESCs) constantly differentiate and proliferate. Furthermore, IECs have 
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unique functions, such as maintaining tolerance to commensal bacteria, and in the 
development and homeostasis of the gut immune cells. 
 Some IECs are specific for the gut and also play a very significant role in the shaping 
the maturation of the mucosal immune system (Peterson and Artis 2014). For e.g., secretory 
IECs like goblet cells secret highly glycosylated mucins into the gut lumen, ensuring that 
there exists a first line of defence against microbes insults and chemical irritants in the colon. 
The importance of mucin production by goblet cells is underscored by a study performed in 
MUC2-deficient mice that developed spontaneous colitis and inflammation-induced 
colorectal cancers (Velcich et al. 2002). Goblet cell-derived trefoil factor 3 (TFF3) further 
contributes to the structural integrity of the mucus (Taupin, Kinoshita, and Podolsky 2000). 
Paneth cells, another class of secretory IECs, release anti-microbial factors locally to fight 
against invading bacteria (Pasparakis M. 2008; Pasparakis M. 2012). IECs are directly 
responsible for transport of secretory immunoglobulins across the epithelial barrier. Following 
their production by plasma cells in the lamina propria, dimeric IgA complexes are 
transcytosed into the intestinal lumen (Peterson and Artis 2014).  
Apart from this role, IECs also act as sensors for microbial interactions within the 
lumen. Pattern recognition receptors such as TLRs, NODs and NLRs, expressed on IECs, 
detect microbial components and activate specific signalling pathways downstream, which in 
turn, regulate genes essential for appropriate mucosal immune cell responses. A landmark 
study demonstrated through the use of TLR-deficient and broad-spectrum antibiotic-treated 
mice that commensal bacteria-derived signals are responsible for epithelial homeostasis and 
repair in a model of chemically induced colitis using DSS (Rakoff-Nahoum et al. 2004). 
Influenced by their interactions with pattern recognition receptors and IECs at the intestinal 
barrier, migratory DCs promote immune tolerance through the differentiation of Foxp3
+
 Tregs 
which is TGF-β1 and retinoic acid (RA)-dependent (Peterson and Artis 2014). After priming 
by intestine-derived antigen-presenting cells in the secondary lymphoid tissues, mature T cells 
exert their tolerogenic or inflammatory effect on the local environment and are subject to the 
direct influence of IECs. Specialized cells known as intraepithelial lymphocytes (IELs) exist 
in close link with the IEC layer; and cross-talk between IELs and IECs maintains immune 
homeostasis at the intestinal barrier. Innate lymphoid cells (ILCs) which are found in gut 
lamina propria, are also subject to various IEC immunoregulatory molecules such as IL-25 
and IL-33 (Wojno, and Artis 2012).  
Recent studies have highlighted the role of many signalling pathways such as NF-B, 
STAT3 and the Wnt/-catenin pathway, which seem to participate and orchestrate the IESC 
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renewal, homeostasis and pathophysiology.NF-B pathway switches on genes responsible 
for cell growth (Cyclin-D), chemokines (CXCLs) and cytokines. Furthermore, IEC-specific 
deletion of IKK which is necessary for the activation NF-κB downstream of TLR signalling 
in mice resulted in enhanced DSS-induced colitis and CAC (Greten et al. 2004; Nenci et al. 
2007). Wnt/-catenin pathway also appears to regulate genes like c-myc for stem cell renewal, 
EphB2/B3 for positioning, TIMP3 for migration and PPAR for differentiation (van de 
Wetering et al. 2002; Lowry et al. 2005). Collectively, these important signalling pathways 
play a central role in cross-talk between the epithelium and the luminal contents. Thus, it is 
very crucial that they are tightly regulated. When epithelial cells are challenged with microbes 
or chemical irritants, on the one hand, these pathways promote epithelial survival, but on the 
other hand, they induce growth factors and cytokines which results in unchecked epithelial 
hyper-proliferation and eventually carcinogenesis. 
 
 
1.6. AOM/DSS animal models of studying inflammatory 
bowel diseases and colitis-associated carcinogenesis  
 
The study of animal models of mucosal inflammation, as a means to examine pathogenesis of 
IBD-linked CRC, has been used in research since almost a half a century. In modern 
immunology, the pathology of the IBD is explored through sophisticated murine models 
(Strober, Fuss, and Blumberg 2002). In past decades, various animal models of human IBD 
have been developed. Experimental models of IBD include chemically-induced models, 
adoptive transfer models, and genetically modified models such as knockout and transgenic 
animals (Perše and Cerar 2012). Accumulating evidence suggests that disruption in epithelial 
barrier integrity contributes to IBD and CAC immunopathology. Support for this observation 
comes from animal models of experimental colitis, in which chemical-induced epithelial 
barrier destruction results in severe intestinal inflammation (Valatas, Bamias, and Kolios 
2015).  
In order to study IBD-related CRC, a two-stage mouse colon carcinogenesis model 
initiated with AOM and promoted by DSS is very often used (Wirtz et al. 2007). Patients with 
UC have an increased risk for the development of colon cancer (Visekruna et al. 2006). 
Hence, to mimic the tumour formation in patients with CAC, the azoxymethane (AOM) / 
dextran sodium sulfate (DSS) model of carcinogenesis is widely used in susceptible strains of 
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mice. AOM is a potent carcinogen and development of cancer caused due to AOM, closely 
mirrors the cancer progression as seen in humans. Following AOM treatment, the epithelial 
cells undergo pathogenesis from minor lesion aberrant crypt foci , to adenoma and malignant 
adenocarcinoma (Takahashi and Wakabayashi 2004).  The in vivo metabolite of AOM causes 
DNA mutations, changing the nucleotides from G:C to A:T (Toole, Pegg, and Swenberg 
1993).  Although widely used, the AOM/DSS model also has its shortcomings. It has been 
reported that the incidence of metastasis is relatively low in AOM-induced adenocarcinoma, 
while in reality colorectal cancer patients have an approximate 50% metastatic rate in regional 
lymph nodes at the time of diagnosis. Some important mutations cannot be completely 
mimicked like the p53 mutation, which is one of crucial steps in human CRCs (Chen and 
Huang 2009). 
DSS is sulfated polysaccharide with a highly variable molecular weight, ranging from 
5 kDa up to 1400 kDa. Colitis is induced by addition of high molecular weight DSS (M.W. 
36,000-50,000) to drinking animals of mice, since DSS is able to penetrate till the mucosal 
membrane in the colon, thereby destroying the colonic epithelial barrier. The DSS colitis 
model is well-characterised by a highly reproducible phenotype and with minimal technical 
requirements for disease development, making it widely used in IBD studies. Acute colitis 
model involves an experimental setup, in which mice are administered high molecular weight 
DSS for short time period, usually lasting 4-9 days. Acute colitis shares many pathological 
features with UC, which includes distal colon edema, watery diarrhoea, bloody stool, weight 
loss, epithelial integrity disruption, neutrophilic infiltration and mucin depletion. The 
inflammation is fully established by day 5 post-DSS treatment and the animals are shown to 
recover from colitis once the DSS administration is stopped (Solomon et al. 2010). In 
contrast, repeated administration of DSS results in chronic inflammation, which is a response 
to persistent injury and/or infection and involves immune cells such as lymphocytes, plasma 
cells, macrophages, and neutrophils (Meira, Bugni, and Green 2008).The DSS-injury in the 
epithelial cells initiates an inflammatory cascade involving various pro-inflammatory 
cytokines involved in innate immunity and Th1/Th17 helper cells, such as IFN-, TNF-, IL-
17A, IL-12 and IL-23 (Valatas, Bamias, and Kolios 2015). 
In summary, the AOM/DSS model of CAC is an extremely useful animal model of 
tumorigenesis, which can be utilised for in-depth analyses of several mechanisms underlying 
the pathogenesis of CAC. Through such animal models, effective and targeted anti-
inflammatory therapies can then be tested as therapeutic treatments in preclinical studies in 
IBD patients who are at a high risk of developing CAC. 
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2. Materials 
 
2.1. Reagents 
 
Reagents Company 
Balanced salts solution (BSS)  Biochrom, Germany 
Bovine serum albumin (BSA)  Sigma-Aldrich, Germany 
Brefeldin A  Sigma-Aldrich, Germany   
Dimethylsulfoxid (DMSO) Sigma-Aldrich, Germany 
Dextran sodium sulphate (DSS)  
(M.W. 36,000-50,000) 
MP Biomedicals, France 
Easycoll (Percoll) Biochrom AG, Germany 
Endothelial cell growth medium PromoCell, Germany 
Ethylenediaminetetraacetic acid (EDTA)  Promega, USA  
Fetal calf serum (FCS)  Gibco, USA 
Formaldehyde  Sigma-Aldrich, Germany 
Foxp3 Fixation/Permeabilisation  
Concentrate and Diluent  
eBioscience, Germany  
Glycine Roth, Germany 
H2O (deionised) B Braun, Germany  
Halt Protease Inhibitor Single-Use Cocktail 
(100x) 
Thermo Scientific, Germany 
Ionomycin  Sigma-Aldrich, Germany 
Isopropanol Roth, Germany 
L-Glutamine Biochrom AG, Germany 
MEM non-essential amino acids (NEAS)  PAA, Austria  
Methanol Roth, Germany 
Page Ruler Plus Pre-stained protein ladder Fermentas, Germany 
Penicillin G  Biochrom AG, Germany 
Phorbol 12-myristate 13-acetate (PMA)  Sigma-Aldrich, Germany 
Phosphate buffered saline (PBS)  Biochrom AG, Germany 
Radioimmunoprecipitation assay buffer 
(RIPA) 
Sigma-Aldrich, Germany 
Rotiphorese Gel 30 Roth, Germany 
Saponin  Sigma-Aldrich, Germany 
Sodium dodecylsulfate (SDS) Sigma-Aldrich, Germany 
Sodium fluoride (NaF) Merck, Germany 
Sodium hydrogen carbonate (NaHCO3) Sigma-Aldrich, Germany 
Sodium orthovanadate (Na3VO4) Sigma-Aldrich, Germany 
Streptomycin  Biochrom AG, Germany 
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2.2. Media, Buffers and Solutions 
 
Buffers Composition 
Balanced salts solution (BSS)  
(pH 7.2)   
9,9g/l BSS,17 mM NaHCO3,10 mM 
HEPES, in sterile H2O  
Bovine serum albumin standard (BSA) 1 mg of BSA in 1 ml sterile H2O 
Cell culture coating buffer (pH 9.5)  50 mM Tris-Base in sterile H2O  
Dulbecco's Modified Eagle Medium 
(DMEM) 
10% FCS, 2mM L-glutamine 
ELISA blocking buffer (Assay Diluent) 3 % BSA [v/v] in 1x PBS 
ELISA wash buffer  0.05% Tween 20 [v/v] in 1x PBS  
Freezing medium (cell lines) 20% FCS, 10% DMSO in final volume of 
250 µl of relevant medium  
Genotyping lysis buffer  50 mM KCL, 10 mM Tris-HCL (pH 9), 
0.1% Triton-X, 0.4 mg/ml Proteinase K  
in sterile H2O 
Laemmeli buffer (loading dye) for  
SDS-PAGE 
12.5% stacking gel buffer, 2% SDS [w/v] 
5% Glycine, 5% β-Mercaptoethanol, 
a spatula-point of bromphenol blue in H2O 
MACS buffer (pH 8.0)  0.5% BSA [w/v], 2 mM EDTA in 1x PBS  
PBS/ 1% FCS  1% FCS [v/v] in 1xPBS  
PBS (1x)  10% 10x PBS [v/v] in sterile H2O 
Saponin buffer  0.3 % Saponin [w/v],2% FCS [v/v], 
in 1x PBS  
RBC lysis buffer  0.17M NH4Cl 
Roswell Park Memorial Institute medium 
(RPMI-1640) 
10% FCS [v/v],2 mM L-Glutamine, 
1% NEAS [v/v],50 μM β-Mercaptoethanol, 
30 mg/ml Penicillin G,50 mg/ml 
SuperSignal West Femto Maximum 
Sensitivity Substrate 
Pierce Biotechnology, USA 
Tissue optimal cutting compound Q path, VWR chemicals, France 
 
Tris (hydroxmethyl) aminomethane (Tris-
Base) 
Acros Organies, Belgium 
Tris-HCl Roth, Germany 
TRI Reagent  Sigma-Aldrich, Germany 
Trypan blue  Gibco, Germany 
Tween 20  EMD Chemicals, Germany 
Western Blot Luminol reagent Santa Cruz Biotechnology, USA 
β-Mercapthoethanol Sigma-Aldrich, Germany 
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Streptomycin in RPMI-1640  
Resolving gel buffer (pH 8.8) 1.5 M Tris-Base in H2O 
RIPA cell lysis buffer 0.5 M Protease inhibitor, 0.5 M EDTA 
20 mM Na3VO4, 20 mM NaF in RIPA 
buffer 
Stacking gel buffer (pH 6.8) 1 M Tris-HCl in H2O 
SDS page running buffer 200 mM Glycine, 25 mM Tris-Base, 0.1% 
SDS (w/v), in H2O 
Western blot blocking buffer 5% milk powder (w/v), 5 M NaCl 
1 M Tris-HCl (pH 7.5), 0.05% Tween20 
(v/v) in H2O 
Western blot transfer buffer 200 mM Glycine, 25 mM Tris-HCl (pH 
6.8), 0.1% SDS (w/v),  20% Methanol (v/v) 
in H2O 
Western blot wash buffer 5 M NaCl, 1 M Tris-HCl (pH 7.5), 0.05% 
Tween20 (v/v), in H2O 
 
2.3. Enzymes 
 
Enzymes Company 
Collagenase D Roche, USA 
Collagenase VIII Sigma-Aldrich, Germany 
DNase I  Roche, USA 
Trypsin-EDTA  Sigma-Aldrich, Germany 
 
2.4. Cytokines  
 
Cytokines Company 
rmIL-12 PreproTech, Germany 
rmIL-6 PreproTech, Germany 
rmIL-4 PreproTech, Germany 
rhTGF-β1  PreproTech, Germany 
rhIL-2  Novartis, Germany  
rhTNF- PreproTech, Germany 
rhIL-1 PreproTech, Germany 
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2.5. Antibodies 
 
2.5.1. Unconjugated antibodies 
 
Name Origin/Company 
α-CD3  cell-culture supernatant of hybridoma 145-2C-11 cells  
α-CD28  cell-culture supernatant of hybridoma 37.51 cells  
α-IL-4  cell-culture supernatant of hybridoma 11B11 cells  
α-IFN-γ  cell-culture supernatant of hybridoma xmg1.2 cells  
α-Catenin  Cell Signaling, USA 
 
2.5.2.Western Blot: Primary antibodies  
 
Name  Company  
α - p65  Santa Cruz ,USA 
α -p105/p50  eBioscience, Germany 
α -IRF4  Santa Cruz ,USA 
α -p-ERK  Cell Signaling, USA 
α-MP3 MPI, Berlin 
α- α4 MPI, Berlin 
α-POMP MPI, Berlin 
α-LMP7 Cell signalling, USA 
 
2.5.3.Western Blot: Secondary antibodies 
 
Name  Company 
Goat α-Rabbit IgG-HRP Santa Cruz, USA 
Goat α-Mouse IgG-HRP Santa Cruz, USA 
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2.5.4.Flow cytometry antibodies 
 
Name  Conjugate Clone Company  
α-CD4  V450 RM4-5 BD Biosciences, Germany 
α -CD8  FITC 53-6.7 BD Biosciences, Germany 
α -MHC II  PE TIB120 purified at Max-Planck-Institute, Berlin 
α -CD11b  FITC M1/70 eBioscience, Germany 
α -Ly-6G  PE 1A8 BioLegend; Germany 
α-IL-17A PE 17B7 eBioscience, Germany 
α-IFN- APC XMG1-2 eBioscience, Germany 
α-Foxp3  PE FJK-16s eBioscience, Germany  
α-IRF4 Alexa Flour- 647 3E4 eBioscience, Germany 
 
2.6. Kits 
 
2.7. Reagents for CD4+ T cell isolation  
 
Name  Company  
α-mouse-CD8 FITC (Clone: 53-6.7)  BD Biosciences, Germany 
α-mouse-B220 FITC (Clone: RA3-6B2)  BD Biosciences, Germany 
α-mouse-CD11b FITC (Clone: M1/70)  eBioscience, Germany 
α-mouse-CD11c FITC (Clone: N418)  eBioscience, Germany 
α-mouse-Ter119 FITC (Clone: TER-119)  eBioscience, Germany 
α-mouse-CD49b FITC (Clone:DX5)  eBioscience, Germany 
Streptavidin-Biotin α- FITC  AG Lohoff, BMFZ (Marburg) 
Biotinylated beads  AG Lohoff, BMFZ (Marburg) 
 
 
Kits Company 
RevertAid First Strand cDNA Synthesis  kit Thermo Scientific, USA 
High Pure RNA Isolation Kit Roche, USA 
Pierce BCA Protein Assay  Thermo Scientific,USA 
Fast SYBR Green Master Mix  Applied Biosystems,USA 
OptEIA ELISA kits BD Biosciences, Germany 
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2.8. Cell lines 
 
Name  Company  
Primary human vascular endothelial cell line  PromoCell 
HT-29  MPI Berlin , Germany  
 
2.9. Chemical inhibitors 
 
Inhibitors Company  
LMP7-specific inhibitor ONX-0914 Onyx Inc., USA 
ONX-0914 formulation buffer 10% (w/v) sulfobutylether--cyclodextrin, 
10mM sodium citrate (pH-6), in Captisol  
NF-B inhibitor BAY 11-7082 Sigma-Aldrich, USA 
BAY 11-7082 formulation substance DMSO 
 
2.10. Primers  
 
Primers 5'-3' sequence 
qRT-PCR 
Murine 
Cxcl1  
fwd  GCT TGA AGG TGT CCT CAG 
rev   AAG CCT CGC GAC CAT TCT TG 
Cxcl2 
fwd  GCG GTC TCA ATG CCT GAA GA 
rev   TTT GAC CGC CCT TGA GAG TG 
Cxcl3 
fwd  CAT CCA GAG CTT GAC GGT GAC 
rev   CTT GCC GCT CTT CAG TAT CTT CTT 
Cxcr1 
fwd  GAC ACT CTC TTA GGA GCC CAC TTG 
rev   CAG GGC CTG GTC AAT GTC A 
Cxcr2 
fwd  GGT GAC TCT GCT GAG CCT TGT  
rev   GCA GGT GCT CCG GTT GTA TAA  
VCAM1 
fwd  TCT CTC AGG AAA TGC CAC CC 
rev   CAC AGC CAA TAG CAG CAC AC 
Hprt1 
fwd  CTG GTG AAA AGG ACC TCT CG 
rev   TGA AGT ACT CAT TAT AGT CAA GGG CA 
Gapdh 
fwd  CTC CAC TCA CGG CAA ATT CA 
rev   GCC TCA CCC CAT TTG ATG TT 
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Human 
VCAM1 
fwd  CCG GAT TGC TGC TCA GAT  
rev   CTC ACC TTC CCG CTC AGA  
lmp7 
fwd  TGA CAC TAC TCC CAG CTC CT  
rev   AAT TCT GTG GGC TCC AGG 
Hprt1 
fwd  TGC TCG AGA TGT GAT GAA GG 
rev   TGT AAT CCA GCA GGT CAG CA 
Genotyping  
Murine 
lmp7 
fwd GTG GCT TTC GCT TTC ACT 
rev TCC CAT GCC TTA ATC TCC 
neo CTC GTC CTG CAG TTC ATT 
rag1 
fwd GAG GTT CCG CTA CGA CTC TG 
rev CCG GAC AAG TTT TTC ATC GT 
neo TGG ATG TGG AAT GTG TGC GAG 
 
2.11. Consumables 
 
Name   Type Company  
Cell culture plates  24/48/96-well  Cellstar, Germany 
Centrigue tubes  15/50 ml BD falcon, Germany  
Cooling centrifuges Megafuge 1.0R  Heraeus, Germany 
Cryomold specimen block  15 mm x 15 mm x 15 mm Tissue- Tek, Japan 
ELISA plates  96 Mirco-well  Nunc, Germany 
ELISA reader  FLUOstar BMG Labtech, Germany 
Flow Cytometer  BD FACSCalibur  BD Bioscience, Germany 
Hemocytometer  Neubauer 0.1 mm  Hecht Assistant, Germany  
Homogeniser UltraTurrax T10 IKA, Germany 
Incubator  HERAcell 240;  
CO2 Incubator  
Thermo Fisher Scientific,  
Germany 
Laminar Air flow   HERAsafe  
Typ 18 (1/PE AC)  
Kendro Lab., Germany 
MACS Multistand  QuadroMACS  Miltenyi, Germany 
Magnetic separation rack  MagneSphere  Promega, USA 
Microscope  DFC 480 Leica, Germany  
Microcentrifuge tubes  1.5/2 ml   
PCR reaction tubes 0.2 ml attach. Cap Greiner bio-one, Germany 
PCR machine  Personal cycler/gradient Biometra 
pH meter InoLab pH Level2 WTW, Germany 
Power Supply Power Pac 1000 Biorad, Germany 
Nylon cell strainer  30 μm/100 µm filter  Corning, USA  
qRT-PCR cycler  TagMan StepOne Life Technologies, USA 
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qRT-PCR plate 96 Fast PCR plate half skirt Sarstedt, Germany 
RNase free tubes Biosphere safe-seal micro 
tubes 
Sarstedt, Germany 
Rotator  Bio RS-24 (PRS-22)  BIOSAN, Latvia  
Round bottom plates  6/12/24-well  Cellstar, Germany 
SDS-PAGE-Chamber Mini-Protean System Biorad, Germany 
Spectrophotometer  Nanodrop ND-1000 Peqlab, Germany 
Thermo block Block Thermostat TCR2000 Roth, Germany 
Western blot Image Station MicroChemie Bistep GmbH, Germany 
Western blot membrane PVDF membrane Roche, USA 
Whatman paper Chromatography paper Whatman Ltd, England 
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3. Methods  
3.1. Mice 
3.1.1. Mice maintenance and breeding  
 
C57BL/6N WT mice were purchased from Charles River Laboratory. lmp7 
-/-
, lmp2 
-/-
,
 
il17af 
-
/- 
, rag1 
-/-
 and rag1 
-/-
 lmp7 
-/- 
(on C57BL/6N background) were bred at the animal facility of 
the Biomedizinisches Forschungszentrum, Philipps-Universität, Marburg. il17af 
-/-
 mice were 
kindly provided by Prof. Dr. Immo Prinz, Institute of Immunology, Hannover Medical 
School, Germany. All mice were housed under standard specific-pathogen free animal facility 
conditions, exposed to 12 h light cycle, were provided with water ad libitum and were given a 
standard rodent pellet diet. All experiments were carried out in accordance with the animal 
ethics approved by R.P. Giessen, Germany. 
 
3.1.2. Mice genotyping 
 
Genotyping for lmp7 
-/- 
and rag1 
-/-
 lmp7 
-/- 
mice was performed regularly in order to confirm 
their homozygous status. Tissue samples from lmp7 
-/- 
and rag1 
-/-
 lmp7 
-/- 
mice were subjected 
to proteolytic lysis in 100 µl of lysis buffer (section 2.2.). Samples were lysed overnight at 55 
°C and proteinase K in the lysis buffer was inactivated by incubating at 95 °C/30 min. Primer 
pairs (section 2.10.) targeting rag1 and lmp7 were used in PCR reactions to confirm gene 
disruption. The following PCR cycling conditions were used for the rag1 primer pair: 94 °C/2 
min, 35 x (94 °C/30 secs, 58 °C /45 secs, 72 °C/45 secs), 72 °C/2 min, 8 °C/hold. The 
following PCR cycling conditions were used for the lmp7 primer pair: 94 °C/5 min, 35 x (94 
°C/30 secs, 58.5 °C /1 min, 72 °C/1 min), 72 °C/5 min, 8 °C/hold. Homozygosity was 
confirmed after PCR products were analysed on 2% agarose gel. For rag1 primer pairs, WT 
band corresponded to 377 base pairs (bp), heterozygous bands to 377 bp and 510 bp, and 
mutant band to 510 bp. For lmp7 primer pairs, WT band corresponded to 474 bp, 
heterozygous bands to 474 bp and 530 bp, and mutant band to 530 bp. 
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3.2. Inducible model of colitis and colitis-associated 
carcinogenesis (CAC) induction  
 
Mice used in all in vivo experiments were age-matched (10-12 weeks) and sex-matched 
(females). Mice were sacrificed using cervical dislocation and removal of organs was done 
using standard surgical procedures. 
 
3.2.1. DSS-induced acute colitis 
 
Dextran sodium sulphate (DSS) is a sulfated polysaccharide and destroys the mucosal barrier 
function throughout the colonic epithelium causing a condition called acute colitis (Wirtz et 
al. 2007) . Acute colitis was induced in mice by administering 2.5% DSS in drinking water for 
5 days. Analyses were performed on day 7 or day 8 after colitis induction. Untreated mice that 
did not receive DSS served as the control group for each experiment. 
 
3.2.2. AOM/DSS-induced CAC 
 
Among the standardised chemically-induced CAC models, the combination of azoxymethane 
(AOM) with intermittent exposure to the inflammatory agent DSS in mice has proven to be a 
stable and reproducible method. This is because it mirrors the aberrant crypt foci-adenoma-
carcinoma sequence that occurs in colon cancer patients with chronic inflammatory bowel 
disease (IBD) (Neufert, Becker, and Neurath 2007) In order to follow this protocol for our 
study, WT and lmp7 
-/- 
mice were injected intraperitoneally (i.p.) using a 0.45 mm x 13 mm 
needle with a single dose of the carcinogen AOM. The dosage of AOM was standardised at 8 
mg/kg body weight for all experiments. The mice were provided with normal drinking water 
till day 5 post-AOM injection. After 5 days, the AOM-treated mice were subjected to 2.5 % 
DSS administered via drinking water for 5 days. This was followed by 14 days of 
administering normal drinking water. This DSS cycle was repeated twice until day 48. 
Following the third DSS cycle, mice were given normal drinking water till day 80 which 
marked the end of AOM/DSS-induced CAC. The weight changes were recorded 3 times a 
week during the course of the experiment. On day 80, experimental analyses for CAC 
development was done. In experiments designed to study chronic colitis phase, mice were 
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sacrificed on day 30 and data analyses was performed. In all experiments, untreated mice that 
did not receive AOM/DSS served as the control group for each experiment.  
 
 
3.3. Application of LMP7-specific inhibitor ONX-0914 
during CAC 
 
To assess the effect of LMP7 inhibition on CAC progression, LMP7-specific inhibitor ONX-
0914 was used in this whole study. A stock solution of ONX-0914 was formulated in captisol 
(see section 2.9.) and to observe its effect it was administered to mice as i.p. at a standardised 
dose of 6 mg/kg. ONX-0914 was given 3 times per week, starting at day five after AOM 
administration, till day 30 for chronic colitis experiments or till day 60 for full course CAC 
experiments. For acute colitis experiments, the mice were administered daily with the same 
dosage of ONX-0914 as used above, starting from day 0 till day 8. For both experimental 
setups, naïve mice were used as control groups. 
 
 
3.4. Histology 
 
Histological techniques were carried out to observe microscopic and morphological changes 
in the mice colons subjected to colitis or CAC induction. 1 cm pieces were placed inside of a 
15 mm x 15 mm x 5 mm cryomold specimen block and filled immediately with tissue optimal 
cutting temperature compound. These molds were then flash frozen instantly using liquid 
nitrogen and then stored at -80 °C till they were cut. Colon tissue cryosections of 
approximately 3-5 µm were stained with hematoxylin and eosin (HE), Periodic acid-Schiff 
(PAS) and -catenin. Slides were examined and scored blindly for tumour development by 
two pathologists using bright field microscopy.  
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3.5. Flow cytometry  
 
Flow cytometry was performed in experiments in which ex vivo or in vitro differentiated cells 
were characterisation for their surface markers, intracellular cytokine production or 
transcription factor expression. For surface staining, cells were initially washed at 500 x g /4 
°C/ 5 min with PBS/1% FCS. The supernatant was removed followed by resuspension in the 
remaining volume (50-100 µl). Relevant fluorochrome-conjugated antibodies were added in 
appropriate dilutions (see section 2.5.4) and incubated for at 4 °C/dark/20 min. The cells were 
then washed at 500 x g/4 °C/ 5 min with PBS/1% FCS and then analysed via flow cytometry. 
If intracellular staining (ICS) was done for cytokines, in vitro differentiated cells were 
washed with PBS/1% FCS and resuspended in restimulation medium composed of 50 ng/ml 
PMA, 750 ng/ml ionomycin and 10 μg/ml brefeldin A. The cell suspension was incubated for 
4 h at 37 °C/5 % CO2. If surface staining was to be done with the samples then it was 
performed at this step before proceeding to the fixation step. Then, the samples were washed 
with PBS once. Afterwards, the samples were fixed with 1 ml of 2% formaldehyde and 
incubated at RT/ 20 min/ dark. After incubation, cells were washed with PBS/1% FCS prior to 
washing with saponin buffer (see section 2.2.). Antibodies with appropriate dilution were 
added to around 100 µl of cells and incubated at 4 °C/ 20 min/dark. The cells were washed 
twice with PBS/1% FCS and the resuspended cells were analysed via flow cytometry. 
For staining of transcription factors, differentiated cells were washed with PBS, 
resuspended and fixed with 400 µl Foxp3 Fixation/Permeabilization Concentrate and Diluent 
according to manufacturer‟s instructions. After incubation for 20 min at 4 °C, cells were 
washed with PBS/1% FCS prior to washing with saponin buffer. The remaining volume (50-
100 μl) was used to resuspend the cells, before antibodies were added and incubated for 
20 min at 4 °C in the dark. Subsequently, cells were washed with saponin buffer and PBS/1% 
FCS. Finally, they were resuspended in 200-300 μl PBS/1% FCS and analysed via flow 
cytometry. 
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3.6. Isolation of colonic lamina propria mononuclear cells 
(LPMCs)  
 
Studies on colonic cells in the lamina propria (LP) of mice are essential for understanding the 
ongoing cellular and immune responses in the gut, especially during inflammation. Lamina 
propria mononuclear cells (LPMC) were enriched from the colonic tissue using a previously 
described method (A Visekruna et al. 2015). Briefly, whole colons were cut open 
longitudinally and washed thoroughly in ice-cold 1X PBS to remove feces. Two colons were 
suspended in 50 ml centrifuge tube containing 25 ml supplemented RPMI medium (see 
section 2.2.) and incubated on a shaker at 150 rpm/37 °C/ 40 min to wash away the remaining 
fecal matter and to loosen the intestinal epithelial cells (IECs). Following this step, the tubes 
were vortexed vigorously in order to release the majority of the IECs. This medium 
containing colons and IECs suspension was then filtered through 100 µm filters to exclude the 
IEC fraction. The remaining colon tissue was cut further into smaller pieces and introduced 
into the digestion medium which contained 0.4 mg/ml of both collagenases D and VIII (see 
section 2.3.) and incubated with constant shaking at 150 rpm/37 °C/45 min. In this digestion 
step, the LPMCs are released from the colonic tissue. 
In order to collect LPMCs, the tubes were centrifuged at 500 x g/4 °C/5 min. The cell 
pellets from the previous step were gently resuspended in 5 ml of 40% Percoll with RPMI 
medium as diluent. 3 ml of 70% Percoll was overlaid with 40% Percoll containing to form a 
discontinuous density gradient, which was centrifuged at 2000 rpm/23 °C/30 min in a 
centrifuge without application of brakes. The LMPCs were carefully collected from the 
interphase using a pippete. Cells were washed with and resuspended in 1 ml of PBS/ 1% FCS 
and stained with -CD11b, -Ly-6G, -MHC-II, -CD3, -CD4, -CD8 and -Foxp3. The 
cells were gated for CD11b
+
Ly-6G
+ 
neutrophils, CD11b
+
MHC-II
+
 macrophages, 
CD3
+
CD4
+
Foxp3
+
 Tregs or CD3
+
CD8
+
 T cells. 
 
 
3.7. Neutrophil characterisation methods  
 
Apart from evaluating neutrophils in the colonic LP, the following techniques were used to 
further compare neutrophils in WT and lmp7
-/-
 mice. 
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3.7.1.Bone marrow neutrophils  
 
The bone marrow is a reservoir for retaining large numbers of either unstimulated or activated 
neutrophils (Kolaczkowska and Kubes 2013). For harvesting them, firstly the femur and the 
tibia from both legs of mice were excised. Most of the muscles and fat was removed during 
dissection. All remaining fat and muscles were scraped off with forceps in a petri dish with 
cold RPMI medium. In order to remove the bone marrow cells, the ends of the bones were cut 
with scissors in order to expose the cavity of bone marrow. With the help of a syringe filled 
with RPMI, all the contents were flushed out into a 50 ml centrifuge tube. This step was 
repeated till the bone marrow cavity was empty. The tubes were then filled with 15 ml RPMI 
and centrifuged at 500 x g /4 °C/5 min.  
For lysing the RBCs in the sample, the cells were gently resuspended in 4 ml of RBC 
lysis buffer NH4Cl (warmed at 37 °C) by pipetting up and down. The reactions were 
incubated at RT/7 min and stopped by the addition of 6 ml of RPMI medium. Then, the cell 
suspension was strained using a 100 µm filter and the resulting filtrate was centrifuged at 500 
x g /4 °C/5 min. The cells were then finally resuspended in 1.5-2 ml of PBS/1% FCS.  
 
3.7.2.Splenic neutrophils 
 
Neutrophils from the blood pass through lymphoid organs such as the spleen and are known 
to accumulate there (Kolaczkowska and Kubes 2013). For obtaining single cell suspension 
from the spleens, they were first removed and transferred into a 15 ml centrifuge tube with 5 
ml of cold BSS (see section 2.2.). They were stored on ice until the following step. Using the 
plunger end of a syringe, spleens were mashed through a 30 µm cell filter into 15 ml 
centrifuge tubes. The cell strainer was rinsed with cold BSS and the filtrate was collected. The 
cells were then centrifuged at 500 x g /4 °C/5 min to obtain a cell pellet. For achieving RBC 
lysis from the cell suspension the same methodology was performed as in section 3.7.1. 
 
3.7.3.Peritonitis  
 
Thioglycollate-elicited peritonitis in mice is used to test the ability of neutrophils to migrate 
towards chemokines. Hence it elicits a robust influx of neutrophils into peritoneal cavity 
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mimicking an inflammatory event. Thus this model was used in WT and lmp7
-/- 
mice in which 
peritonitis was induced by a single i.p. injection of 1.4 ml of 3% sterile thioglycollate. 700µl 
of thioglycollate was injected on either side of each mouse. After 4 hours, mice were 
sacrificed and the cells from the peritoneum were recovered by peritoneal lavage, which was 
done by carefully flushing 10 ml of cold RPMI medium with the help of a syringe with a 0.9 
mm x 40 mm needle. The cell suspension was filtered using a 100 µm filter and centrifuged at 
500 x g/4 °C/5 min. The cell pellets were washed with and resuspended in 1 ml of PBS/ 1% 
FCS and stained for neutrophils. 
Samples from bone marrow, spleen and peritoneum were first treated with the Fc-
receptor blocking antibody CD16/32 at 4 °C/ 5 min and then stained with -CD11b and -Ly-
6G. This was done in order to analyse them for neutrophil population using flow cytometry.  
 
 
3.8. Colon ex vivo explant culture  
 
In order to analyse cytokines secreted by physiologically intact sections of colon ex vivo, 
colon pieces were cultured in suitable medium followed by harvesting this medium for further 
analyses. To do this, 1-cm-sections of the proximal colon were washed with PBS to remove 
feces. For every 50 mg of colon, 1 ml of RPMI medium (see section 2.2.) was added to the 
colon explant in a 24-well cell culture plate. The cell culture plates were incubated at 37 °C/ 
5% CO2. Colon culture supernatants were harvested after 24 h and aliquots were frozen at -80 
°C till the cytokine concentrations were determined by enzyme-linked immunosorbent assay 
(ELISA). 
 
 
3.9. Biochemical Methods  
 
3.9.1. Enzyme-linked immunosorbent assay (ELISA) 
 
ELISA is a photometric assay made for detection as well as quantification of various 
substances such as proteins. To quantify cytokines IL-6, TNF- and IL-17A in colon ex vivo 
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explant supernatants, ELISA was performed according to manufacturer‟s instructions for 
OptEIA ELISA kits. In short, 96-well plates were coated with 50 µl capture antibody and 
incubated overnight at 4° C. Plates were washed three times and blocked with assay diluent 
(see section 2.2.) for 1 h/RT. Then the plates were re-washed after which a serial dilution 
starting from 1000 pg/ml till 15 pg/ml of respective standard protein was prepared. 
Appropriately diluted samples from colon ex vivo explants as well as standards were added to 
the wells in duplicates. The plate was then incubated at 4 °C overnight.  
The following day, freshly made working detection solution, which contained the 
detection antibody along with streptavidin-HRP conjugate, was prepared. After five washing 
steps, 50 µl of the detector solution were pipetted into each well followed by an incubation of 
the plate for 1 h/RT. After seven washes, 50 µl TMB substrate was added to the wells and 
incubated for 30 min in the dark. 25 µl of stop solution was then added to stop the reaction. 
Concentrations of IL-6, TNF- and IL-17A were determined photometrically at 450 nm. 
Wavelength correction was performed subtracting the absorbance at 570 nm from the 
absorbance at 450 nm.  
 
3.9.2. Colon tissue and cell preparation for Western blot  
 
To extract cellular protein in whole tissue or cell culture for further downstream processing, 
they are firstly subjected to lysis. Approximately 50–100 mg colon pieces were cut from the 
proximal colons. Pieces were cut open and washed thoroughly in cold 1X PBS to remove any 
feces. In case of cell culture suspension, at least 3 million cells per sample were harvested and 
washed once with cold 1X PBS.  
The colon tissue was homogenized using a homogenizer in microcentrifuge tubes 
using approximately 500–700 µl of RIPA buffer (section 2.2.). For processing cell culture 
samples, approximately 3 million cells were lysed in microcentrifuge tubes by repeated 
pipetting in 100–200 µl RIPA buffer. The cells were then incubated on ice for 10 min with 
intermittent vortexing. This step was repeated twice to ensure total lysis of the tissue or cells 
in the lysis buffer. The samples were centrifuged at 8000 rpm/4 °C/5 min to exclude cell 
debris. Supernatants were transferred into a fresh tube and were either used immediately or 
stored at -80 °C for future use. 
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3.9.3. Protein estimation for Western blot  
 
Total protein in the lysed tissue and cell samples was quantified using a BCA assay kit 
according to manufacturer‟s instructions. In brief, protein standard was made using a serial 
dilution of bovine serum albumin (BSA) in 1X PBS (assay range: 20-1000 µg/ml). The 
samples were also diluted with 1X PBS in the ratio of 1:4 till 1:32. 20 µl of each dilution was 
plated in 96-well plates in duplicates. 180 µl of BCA reagent (A:B/50:1) was added to each 
well. Incubation was done at 37 °C for 30 min. The concentration of protein in the samples 
was determined photometrically at 550 nm. 
 
3.9.4. Western blot protocol  
 
Immunoblotting or Western blot is a technique used to detect individual target proteins in a 
protein pool. 10–20 μg of protein were mixed with equal ratio of Laemmli sample buffer 
(section 2.2.) and was denatured at 95 °C/ 10 min. Then the samples were separated by 
electrophoresis in Tris-glycine buffered SDS-polyacrylamide gels with 5% stacking gel and 
12% resolving gel (section 2.2.). Gels were run in Tris-Glycine Running Buffer (section 2.2.) 
at 80 V/10–15 min and then for at 120V/70–90 min along with a protein marker. Transfer 
onto a PVDF membrane was done using transfer buffer (section 2.2.) for 1 h at 4.4 mA/cm
2
. 
Membranes were blocked using blocking buffer (section 2.2.) either for 1 h / RT or at 4 °C 
overnight on a shaker. The following day, the membrane was incubated with the relevant 
primary antibody (section 2.5.2.) overnight at 4 °C on a shaker. The membrane was then 
washed 3 times/10 min with wash buffer (section 2.2.) at RT and incubated with relevant 
secondary antibody (section 2.5.3.) for 1h / RT on a shaker.  
For detection of the 20S proteasome subunits and POMP, the quantitative two-colour 
fluorescent immunoblot analysis was performed as described previously (Joeris et al. 2012). 
GAPDH was used as the loading control. Normalised band intensities were calculated by 
dividing the band intensity of target protein by that of the loading control GAPDH.  
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3.10.Molecular Biology Methods  
 
3.10.1. Total RNA extraction using TRI Reagent 
 
Tri Reagent (section 2.1) is a mixture of guanidine thioacyanate and phenol, which effectively 
separates DNA, RNA and protein on homogenisation or lysis of tissue sample. Hence, it was 
used to isolate total RNA from tissue samples. 50–100 mg of colon tissue samples were 
homogenised on ice in 1 ml of TRI Reagent using a homogeniser. Tissue samples were 
centrifuged at 12,000 x g /4 °C/10 min to remove fat, muscle and cell debris. The clear 
supernatant was transferred to a fresh 2 ml microcentrifuge tube. After the material was 
homogenized or lysed in TRI Reagent, samples were either stored at –80 °C or used 
immediately. Next, samples were allowed to stand at RT/10 min for the nucleoprotein 
complexes to dissociate. 200 µl of chloroform per ml of TRI Reagent was the added to the 
samples. The samples were shaken vigorously for 15 secs, and allowed to stand for 10 min at 
room RT. The resulting mixture was centrifuged at 2000×g/ 4 °C/15 min.  
This step separated the mixture into 3 phases: a red organic phase (containing protein), 
an interphase (containing DNA), and a colourless upper aqueous phase (containing RNA). 
The aqueous phase was transferred to a fresh microcentrifuge tube and 500 µl of 2-propanol 
per ml of TRI Reagent was added to it. After gentle mixing, the samples were allowed to 
stand for 10 min/RT. The tubes were then centrifuged at 12,000 x g /4 °C/10 min. The RNA 
precipitated on the side and bottom of the tube in the form of a pellet. This pellet was washed 
twice with 70% ethanol at 7500 x g /4 °C/5 min in order to remove residual salts. Excess 
ethanol was removed by inverting the tubes gently on tissue. RNA pellet was air dried for 10–
15 min at RT. 30–50 µl of nuclease-free and deionised water was added depending on the size 
of RNA pellet in order to dissolve it. The microcentrifuge tubes containing RNA pellets were 
then incubated at 60 °C /15–20 min with intermittent shaking. The yield and concentration of 
total RNA was determined using a NanoDrop. 
 
3.10.2. DNase treatment 
 
As far as possible, amplification of PCR products derived from contaminating genomic DNA 
was excluded by the use of intron-exon spanning primer pairs. If required, total RNA was 
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treated with DNase I prior to cDNA synthesis to ensure no contamination from genomic 
DNA. Up to 10 µg of RNA samples were mixed with 2.5 U of DNase I along with other 
essential components such as incubation buffer, RNase inhibitor and water according to 
manufacturer‟s instructions. The samples were incubated at 37 °C/ 20–25 min with 
intermittent mixing. The RNA samples were recovered with another isolation step which 
followed the protocol involving TRI Reagent (section 2.1.). The yield and concentration of 
total RNA was determined using NanoDrop. 
 
3.10.3. Total RNA extraction using a kit  
 
RNA was extracted from cell cultures using a RNA isolation Kit. The starting material was at 
least 2 million cells per sample. In brief, cells were resuspended in 200 μl PBS followed by 
the addition of 400 μl Lysis/Binding Buffer. The samples were vortexed for 15 secs and then 
transferred to a High Pure Filter Tube plus collection tube. Approximately 700 µl of sample 
was pipetted into the upper reservoir of the filter tube. The samples were centrifuge 8000x g/ 
30 secs/RT. The flow-through was discarded and for each sample a mixture of 90 μl DNase I 
Incubation Buffer and 10 μl DNase I, was added to the filter tube. Samples were incubated at 
37 °C/20 min. After this step, samples were sequentially washed with 500 μl Wash Buffer I, 
500 μl Wash Buffer II and then again with 200 μl Wash Buffer II. All the washing steps were 
done at 8000 g/RT/30secs. The samples were eluted in approximately 25–30µl of deionised 
water and were wither used directly in quantitative real-time PCR (qRT-PCR) or stored at -80 
°C for later analysis. 
 
3.10.4. Complementary DNA (cDNA) synthesis for quantitative 
real-time PCR (qRT-PCR) 
 
cDNA synthesis was performed to reverse transcribe DNA from an RNA template using  
RevertAid First Strand cDNA Synthesis Kit. Briefly, a minimum of 500 ng RNA was used in 
each reaction. According to the manufacturer‟s instructions, in a 200 µl microcentrifuge tube, 
the RNA samples were mixed with specified amounts of reverse transcriptase, reaction buffer, 
RNase inhibitor, oligo-dT primers and nuclease-free water. The following cycle was used in a 
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PCR cycler: 42 °C/ 1h, 70 °C/5 min and 8 °C/ hold step. The cDNA was directly used for 
qRT-PCR. 
 
3.10.5. qRT-PCR protocol  
 
qRT-PCR was performed on a qPCR device to detect mRNA expression. The master mix 
used for all the experiments was Fast SYBR Green Master Mix. All reactions contained 2.5 µl 
of appropriately diluted cDNA and a final concentration of 250 nM for all the reactions. The 
total reaction volume was 20 µl. The following programme was used for amplification: 95 
°C/10 min, 35 X (95 °C/15 secs, 60 °C/35–45 secs). Specificity of the amplicons was 
confirmed by evaluating the melting curve of the products. The primer pairs used for this 
technique are listed in the section 2.10. Quantification of cDNA was carried out by 
normalisation to expression of housekeeping genes Hprt-1 or Gapdh using the Ct method. 
 
 
3.11.in vitro experiments 
 
3.11.1. CD4+ T cell culture experiments  
3.11.1.1. IL-17A and IFN- expression profile in ONX-0914-treated CD4+ T-
cells 
 
CD4
+
 T cells from WT and lmp7 
-/-
 mice were isolated from spleen and lymph nodes by 
negative magnetic cell sorting. Briefly, cell number was adjusted to 10
8 
cells per 250 µl of 
MACS buffer (section 2.2.). 3 µl of the antibody-mix containing FITC-conjugated antibodies 
against B220, CD11b, CD11c, Ter119, CD49b and CD8 was added per 10
8
 cells. This 
mixture was incubated for at 4 °C/10 min. Next, the cells were washed with MACS buffer and 
then resuspended in 100 µl MACS buffer along with 1 µl biotin-streptavidin-conjugated 
α-FITC antibodies for 108 cells. Incubation was done at 4 °C/15 min and then cells were 
washed with MACS buffer again. The pellet was resuspended in 1.5 ml MACS buffer per 10
8
 
cells. To this suspension, 50 µl biotinylated beads were added and reaction tubes were placed 
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on a rotator for 4 °C/30 min. Tubes were placed on a magnetic separation rack for RT/30 min 
and then careful removal of the supernatant was done which contained the CD4
+
 fraction. The 
purity of the isolated CD4
+ 
cells was determined by flow cytometry and was approximately 
90%. The isolated CD4
+
 T cells were activated with plate-bound α-CD3 (5 µg/ml) and soluble 
α-CD28 (1 µg/ml). For T cell differentiation the following polarising conditions were used:  
 
Medium components Th0 Th1 Th17 Tregs 
α-IFN-γ                 5 µg/ml  - 5 µg/ml 5 µg/ml 
α-IL-4  10% 10% 10% 10% 
rhIL-2  50 U/ml 50 U/ml 50 U/ml 100 U/ml 
rhTGFβ1  -  - 1 ng/ml 1 ng/ml 
IL-6   -  - 40ng/ml  - 
IL-12  10ng/ml  -  -  - 
 
CD4
+
 T cells from WT or lmp7 
-/-
 were differentiated for 3 days in Th0-, Th1-, Th17- 
and Treg- polarising conditions. On day 3, after restimulation (section 3.5.) cells were 
analysed for IL-17A and IFN-γ production by ICS. Foxp3 also analysed by flow cytometry 
only in Tregs. For determining the effect of LMP7-inhibitor ONX-0914 and NF-B inhibitor 
BAY 11-7082 (section 2.9.) on IL-17A, IFN- production and IRF4 expression, CD4+ T cells 
from WT mice were cultured for 3 days in Th17 polarising conditions. On day 3, cells were 
tested for IL-17A, IFN- and IRF4 expression via flow cytometry. 
 
3.11.1.2.  NF-κB (p105/50) and IRF4 immunoblot expression in ONX-0914-
treated CD4
+
 T cells 
 
To follow the processing of p105/p50 closely in the presence of ONX-0914, a kinetic-based 
study was performed. CD4
+
 T cells were isolated from spleen and mesenteric lymph nodes of 
WT mice and restimulated for 4 h. At least 2 million CD4
+
 T cells were cultured with or 
without 400 nm ONX-0914 in a 6-well plate and incubated at 37 °C/ 5% CO2. Cells were 
harvested at 0, 15, 30 and 60 min. Samples were processed for Western blot (section 3.9.2.). 
The blot was stained for -actin as loading control and NF-κB (p105) as the target protein. 
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The blot was also stained for p-ERK which served as an experimental control. Untreated cells 
served as negative control. 
For observing the expression profile of IRF4 under the influence of ONX-0914, a 
similar experimental set up was established. WT Th17 cells were cultured for 16 h in the 
presence of 200 nM or 400 nM ONX-0914. Untreated cells served as the negative control. 
Subsequently, after 16 h the cells were harvested and immunoblot analysis for IRF4 was 
performed using -IRF4 antibody and -actin as loading control. 
 
3.11.2. Cell line experiments 
 
3.11.2.1.  Primary human umbilical vein endothelial cells (HUVECs) 
 
HUVECs were used to observe the effect of LMP7 inhibition on expression endothelial 
adhesion molecules which the neutrophils use to migrate across the endothelium. They were 
cultured in endothelial cell growth medium. Cells grown till passages 3-5 were used for all 
experiments.  
Cells were seeded at a density of 1 x 10
5 
in 6-well plates. They were allowed to adhere 
overnight. Adherence was checked under a light microscope before every experiment. For 
stimulation experiments, HUVECs were pretreated with or without 100 nM ONX-0914 for 2 
h. Both untreated and ONX 0914-treated cells were then further stimulated with 10 ng/ml 
recombinant human TNF- and then harvested after 6 h. Harvested cells were washed once 
with 1X PBS and centrifuged for 8000 rpm/4 °C/5 min and frozen at -80 °C until RNA 
isolation and qRT-PCR was performed. 
 
3.11.2.2.  HT-29 
 
Human colon adenocarcinoma cell line HT-29 was used to study expression of chemokines in 
the context of colon cancer. They were cultured in DMEM (section 2.2.). Cells were used up 
until passage 20 for all experiments. Cells were seeded at a density of 1 x 10
5 
cells
 
in a 12-
well plate. They were allowed to adhere overnight. Adherence was checked under a light 
microscope before every experiment.  
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For stimulation experiments, HT-29 was treated with or without 10 ng/ml rhIL-1. 
Both untreated and IL-1-treated cells were harvested after 2 h. Cells which were left 
untreated served as the negative control for all experiments. Harvested cells were collected 
and centrifuged for 8000 rpm/4 °C/5 min and frozen at -80 °C until RNA isolation and qRT-
PCR was performed. 
 
3.11.2.3. Subculture and cryopreservation of cell lines 
 
Cell lines were always grown at 37 °C/ 5% CO2 in 75 cm
2
 tissue culture flasks till they were 
80–90% confluent. For subculturing the cell lines, cells were treated with trypsin-EDTA 
(0.05%), incubated at 37 °C/ 5% CO2 until the cells round up when checked under a light 
microscope. HUVECs were incubated for 5 min and HT-29 for about 6–8 min. Cells were 
then centrifuged at 500 x g/4 °C/5 min. The resultant cell pellet was resuspended in 
appropriate medium and split in the ratio of 1:4 in case of HUVECs and 1:8 in case of HT-29. 
For freezing the cell lines, they were harvested and resuspended in 1 ml of appropriate 
medium. The cells were incubated on ice for one hour. During this incubation, cells were 
counted with 1:20 dilution of Trypan blue. Cell number was adjusted to 1.5–2 million cells 
per cyrotube. Equal volume of freezing medium (section 2.2.) was added dropwise & shaken 
the continuously. The cryotubes were stored in cold isopropanol at -80 °C overnight. After 
this step, they were shifted to liquid nitrogen tank for long-term storage. They were regularly 
checked for the absence of mycoplasma contamination. 
 
 
3.12.  Statistics  
 
Data are presented as mean ± SEM and were analysed with GraphPad Prism (GraphPad 
Software). Significance testing was done by either Student t-test or 1-way ANOVA followed 
by Bonferroni‟s correction. 
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4. Results 
 
4.1. Decreased abundance of proteasome subunits in 
LMP7-deficient mice after DSS treatment 
 
In mice and humans, cellular immunoproteasomes have been shown to be upregulated during 
intestinal inflammation (van Deventer and Neefjes 2010; Visekruna et al. 2006; Schmidt et al. 
2010). Previously, it was demonstrated that immunoproteasome (iP) subunit LMP7 increases 
the rate of proteasome neogenesis (Heink et al. 2005). Our working group could show that 
during Listeria monocytogenes infection, the total amount of 20S proteasomes was decreased 
in mice lacking LMP7 as compared to WT animals (Joeris et al. 2012).  
To examine if the LMP7 deficient animals could increase the total proteasome content 
during inflammation, WT and lmp7
-/-
 mice were treated with a single round of DSS to induce 
acute colitis and the expression of representative subunits were evaluated at protein level. It 
was observed that WT mice enhance the expression of LMP7 subunit after induction of 
intestinal inflammation (Fig. 1A). It was previously shown that -MP3 antibody recognising 
majority of structural proteasome subunits can be used to quantify the proteasome content in 
the cell (Joeris et al. 2012). To compare the expression of pan-20S proteasome subunits in 
DSS-treated WT and lmp7
-/-
 mice, the Western blot analysis was performed using-MP3 
antibody and the overall band intensity was quantified by densitometry. Of note, during the 
progress of acute colitis, lmp7
-/-
 mice failed to increase the proteasome quantity in the 
inflamed colon, when compared to WT mice which could upregulate all proteasome subunits. 
The expression at protein level of representative proteasome subunits in both groups were 
evaluated at day 0, 4, 8 and 12 days following DSS exposure. Densitometric analysis of 
Western blots revealed that the expression of all structural subunits of the 20S proteasome 
complex from the inflamed colon in the WT mice rise significantly from day 8 onwards which 
is indicative of ongoing inflammation. On the contrary, in lmp7
-/-
 colons, the expression of 
these subunit remains constant even after 12 days of exposure to DSS (Fig. 1B). The same 
observation holds true for a single structural proteasome subunit 4; here, the expression 
increase two-fold in WT mice on day 12 after induction of acute colitis, whereas it does not 
change significantly in the lmp7
-/- 
mice (Fig. 1C).  
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               A                                                                           B 
                                                                                  
            C                                                               D 
                                                                
Figure 1. Abundance of proteasome subunits in lmp7 
-/-
 mice after DSS treatment. (A) Acute 
colitis was induced in WT mice by giving 2.5 % DSS in drinking water until day 5. The western blots stained 
for LMP7 and GAPDH were quantified by densitometric analysis for the indicated days. (B-D) WT and lmp7-/- 
mice were administered a single round of 2.5% DSS for 5 days. Densitometric quantification of immunoblot 
analyses for expression of pan-20S subunits (MP3 Ab) (B), 4 (C) and POMP (D) were performed on indicated 
days after exposure to DSS. The membranes were stained against GAPDH as loading control. Data represent 
mean ± SEM where n=10-12 mice per group. Three independent experiments were performed.  
 
As the rapid degradation of the proteasome maturation protein (POMP) is a 
physiological signal for termination of proteasome maturation and LMP7 has been described 
to have a high affinity to bind to POMP, the kinetics study of POMP expression was done in 
the colons of WT and lmp7
-/-
 mice after DSS treatment. Notably, the massive accumulation of 
the POMP was detected in both naïve and DSS-treated colons of lmp7
-/- 
mice in comparison to 
WT animals suggesting a reduced capacity to incorporate the remaining proteasome subunits 
into the mature 20S proteasome in the absence of LMP7. On the other hand, in WT mice there 
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was only a slight and transient increase in expression starting day 8 as compared to day 0 
(Fig.  1D).  
It can be concluded that lmp7
-/-
 mice are unable to efficiently complete proteasome 
maturation in the colon during ongoing inflammation and hence do not possess a fully 
functional iP which would normally assist the constitutive proteasome during colonic 
inflammation. 
 
 
4.2. Absence of LMP7 results in highly attenuated colitis-
associated carcinogenesis (CAC) in mice  
 
Recently, it has been reported that induction of immunoproteasomes during the inflammation 
is crucially involved in the regulation of pro-inflammatory activity of mucosal immune cells 
(Schmidt et al. 2010; Basler et al. 2010). After concluding that during acute colitis lmp7
-/-
 
mice possess a reduced amount of 20S proteasomal subunits in relation to WT mice (Fig. 1, 
A-D), we were wondering what the impact of LMP7 deficiency is on the progression of 
inflammation-associated tumorigenesis. Following the induction of colitis-associated 
carcinogenesis (CAC) by administering the carcinogen AOM accompanied by an 
inflammatory agent DSS (Fig. 2A), tumorigenesis in the distal colon was observed to be 
highly restricted in lmp7
-/-
 mice. In contrast to the WT mice, AOM/DSS-treated lmp7
-/-
 mice 
did not develop full-scale inflammation-driven carcinogenesis even after completion of 80 
days following induction of CAC. During the course of the experiment, WT mice lost 
considerable body weight accompanied by occurrence of multiple macroscopic, distal colonic 
tumours. On the other hand, lmp7
-/-
 mice lost comparatively less body weight with almost no 
visible tumours in the colons (Fig.2B). The distal colon of each WT mouse had 8–11 tumours 
on an average. Conversely, lmp7
-/-
 mice had at most about 1–2 small tumours in their distal 
colons (Fig. 2C).  
 In summary, these data collectively suggest that absence of immunosubunit LMP7 
protects the mice from developing tumours in the distal colons after CAC induction. 
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Figure 2. Consequence of LMP7 deficiency on colitis-associated carcinogenesis (CAC) in mice. 
WT and lmp7-/- mice were subjected to the AOM/DSS CAC-induction protocol and naïve WT were used as 
controls in these experiments. (A)  Scheme for the experimental course for CAC induction using 8 mg/kg AOM 
and 3 cycles of 2.5 % DSS over a course of 80 days. (B) The change in weight monitored in naïve and 
AOM/DSS-treated WT and lmp7-/- mice over a period of 80 days. (C) Colonic tumour incidence in naïve and 
AOM/DSS treated mice on day 80. Data represent mean ± SEM, where n=10-12 mice per group. ***P<0.001.  
 
 
4.3. Lack of LMP7 results in restricted colonic 
tumorigenesis 
 
In order to evaluate tumorigenesis in a greater detail, three different immunohistochemical 
stainings were performed, namely Haematoxylin and Eosin (HE), Periodic acid–Schiff (PAS) 
and -catenin, which further supported and extended the observation that only AOM/DSS-
treated WT developed multiple tumours.  
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Figure 3. Immunohistochemical analysis of CAC progression in WT and lmp7
-/-
 mice. WT and 
lmp7-/- mice were subjected to the AOM/DSS CAC-induction protocol using 8 mg/kg AOM and 3 cycles of 2.5 
% DSS over a course of 80 days. Naïve WT mice were used as controls in these experiments. Representative 
images of HE (A) PAS (B) and -catenin (C) stained colon sections of control or AOM/DSS-treated WT and 
lmp7-/- mice on day 80. Scale bars: 100µm for HE andcatenin, 200µm for PAS staining. 
 
HE staining revealed that AOM/DSS-treated WT colons had adenocarcinomatous 
intestinal epithelial cells (IECs).  Conversely, lmp7
-/-
 mice colons showed that the epithelium 
was as intact as that in untreated colons of WT mice, with almost no detectable 
adenocarcinoma formation (Fig. 3A). From these data, it can be concluded that, upon CAC 
induction, lack of LMP7 subunit protects the mice from intestinal tumorigenesis. PAS 
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staining done on colon sections from WT animals treated with AOM/DSS showed a marked 
reduction in mucin production, indicated by the lack of goblet cells. lmp7 
-/-
 mice, however, 
did not display any abnormal goblet cell appearance. Moreover, in lmp7
-/-
 mice the mucin 
production seemed comparable to the naïve, untreated colon sections (Fig. 3B). To summarise 
the finding based on PAS staining, the absence of any damage to the mucosa indicated an 
intact epithelial barrier and integrity with normal levels of mucous production in AOM/DSS-
treated lmp7
-/-
 mice. 
-catenin, whose nuclear translocation is an important step in the development of 
colorectal cancer, was compared in AOM/DSS-treated WT and lmp7
-/-
 mice. 
Immunohistochemical staining revealed that in the AOM/DSS-treated WT IECs, -catenin 
was found to be distributed in an irregular diffused membranous, cytoplasmic and nuclear 
pattern within the cells. In contrast, lmp7
-/-
 IECs exhibited relatively normal cytosolic and 
membranous expression of -catenin which was comparable to -catenin localisation in the 
untreated colon sections from WT mice (Fig. 3C). In conclusion, -catenin was mostly 
localised in normal cytosolic and membranous pattern in colonic lmp7
-/-
 IECs thereby 
indicating a lack of tumorigenesis.  
In summary, upon CAC induction lmp7
-/-
 mice were highly protected from developing 
higher clinical stages of inflammation-driven carcinogenesis as compared to their WT 
counterparts which developed colon cancer. 
 
 
4.4. Reduced NF-κB levels in LMP7-deficient mice after 
induction of CAC 
 
NF-B activation is seen in many solid tumours and increased activity of this transcription 
factor has been detected in both inflammatory microenvironment of tumors and in already 
transformed tumour cells (Karin 2009). As proteasomes are directly responsible for the 
activation of classical and alternative NF-B signalling pathways, we hypothesised that the 
lack of iP subunit LMP7 might lead to reduced NF-B activity during ongoing intestinal 
carcinogenesis.  
To assess the impact of LMP7 on NF-B activation during the progression of CAC, 
various NF-B subunits were tested at protein level by Western blot analysis in AOM/DSS-
treated WT and lmp7
-/-
 mice. On day 80 after CAC induction, AOM/DSS-treated lmp7
-/-
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colons displayed a significantly reduced expression of tested NF-subunits when compared 
to WT mice. WT colons showed a strong increase in NF-subunit p65 expression which is  
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Figure 4 . NF-B levels in LMP7-deficient mice at day 80 after induction of CAC. Distal colon 
samples of AOM/DSS-treated WT and lmp7-/- mice collected at day 80 were tested for various NF-B 
subunits by Western blot analysis. NF-B subunit p65 was analysed by western blot (A) and densitometric 
analysis (B). Densitometric data is representative of two independent experiments and is normalized to p65 
expression in the colon of naïve WT mice. **P<0.01. Colons of AOM/DSS-treated WT and lmp7-/- mice 
were also analysed by Western blot from day 80 samples for c-Rel (C) and p105/p50 (D). -Actin or -
Tubulin served as loading controls as indicated. A representative of two experiments is shown. Data represent 
mean ± SEM, where n = 10-12 per group. 
 
indicative of enhanced activation of NF-B during ongoing tumorigenesiswhereas the 
amount of p65 was downregulated in AOM/DSS-treated lmp7
-/-
 colons (Fig. 4A). This data is 
also supported by densitometric analysis of the Western blot which indicates a three-fold 
reduction in p65 protein expression in lmp7
-/-
 colons in comparison to the WT group (Fig. 
4B). Similarly, in correlation to WT mice, expression levels of NF-subunits c-Rel and NF-
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B1 (p105/p50) on day 80 after CAC induction were observed to be highly reduced in LMP7 
deficient mice (Fig. 4, C and D).  
These results are strongly indicative of substantial downregulation of NF-activity 
in lmp7
-/-
 mice which might be significantly affecting the course of carcinogenesis. 
 
 
4.5. Diminished pro-inflammatory cytokines in innate and 
adaptive immune system arms of LMP7-deficient mice 
during inflammation 
 
Chronic inflammation is sustained through the function of various pro-inflammatory 
mediators, including TNF-, IL-6, and IL-17A subsequently leading to invalidation of anti-
tumour immunity and promotion of accelerated tumorigenesis (West et al. 2015) In order to 
determine whether lmp7
-/-
 mice could evoke and sustain a chronic inflammatory phase after 
AOM/DSS-treatment, pro-inflammatory cytokines secreted by ex vivo colon explants were 
measured by ELISA during chronic colitis phase. Diminished secretion of pro-inflammatory 
cytokines such as TNF-IL-6 and IL-17A in lmp7-/- mice was evident of a highly attenuated 
inflammatory response.  
On day 30 after CAC induction, in contrast to WT mice, ex vivo colonic explants of 
lmp7
-/-
 mice secreted less than half of cytokine IL-6 (Fig. 5A). Additionally, high levels of 
F-was detected in supernatants from WT colon explants, whereas this cytokine was not 
detectable in lmp7
-/-
 colon cultures (Fig. 5B). It is apparent from these data that the 
upregulation of pro-tumorigenic cytokines like TNF-andIL-6 needs enzymatic activity of 
proteasome immunosubunit LMP7.
Apart from TNF-andIL-6, the cytokine IL17-A has been shown to be crucially 
involved in the development of inflammation-driven carcinogenesis (Hyun et al. 2012). A 
recent study supports and extends this concept by demonstrating that both innate and adaptive 
immune cellular sources contribute to the promotion of colorectal cancer (Housseau et.al. 
2016). Interestingly, almost negligible amounts of IL-17A were detected in colon of lmp7
-/-
 
mice as compared to the strong secretion of this cytokine in WT animals after induction of 
CAC (Fig. 5C). Although, the majority of IL-17A is likely to be derived from Th17 cells, the 
contribution of innate cells cannot be excluded.  
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Figure 5. Pro-inflammatory cytokines secretion during chronic colitis phase in LMP7-
deficient mice after CAC induction. (A-C) Supernatants from ex vivo colon explants of naïve or 
AOM/DSS-treated WT and lmp7 -/- mice at day 30 after induction of CAC were measured by ELISA for IL-6 
(A),  TNF-(B) and IL-17A (C). Data represent mean ± SEM, where n = 10-12 mice per group. n.d.: not 
detectable, *P<0.05, **P<0.01, ***P<0.001. (D) Supernatants from ex vivo colon explants of naïve or DSS-
treated rag1-/- and rag1-/- lmp7 -/- mice at day 8 after colitis induction were estimated by ELISA for the 
secretion of IL-17A. Data represent mean ± SEM, where n = 8 mice per group. 
 
To test the consequences of LMP7-deficiency on the ability of innate cells to produce 
this pro-inflammatory cytokine during inflammation, rag1
-/- 
lmp7
-/- 
mice were subjected to 
acute colitis. IL-17A secretion was measured from ex vivo colon explants at day 8 after 
initiation of DSS treatment. Of note, rag1
-/- 
lmp7
-/- 
mice, which possess LMP7 deficient 
colonic innate immune cells, failed to mount an augmented IL-17A cytokine response 
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following DSS treatment, whereas the control group of rag1
-/-
 animals was able to secrete IL-
17A during inflammation. (Fig. 5D). These observations strongly suggest that LMP7 is 
responsible for controlling IL-17A cytokine production in both Th17 and innate immune cells. 
In summary, LMP7-deficiency in immune cells fails to promote colonic pro-
inflammatory cytokine response upon inflammation which limits the state of chronic colitis 
which is needed to sustain colonic carcinogenesis. 
 
 
4.6. Stable neutrophil homeostasis in bone marrow and 
reduced splenic neutrophils in naïve lmp7-/- mice 
 
Recently, it has been demonstrated that recruitment of neutrophils to colon favours the 
progression of colorectal carcinogenesis (Shang et al. 2012; Wang et al. 2014). Moreover, 
results from our research group revealed defective influx of inflammatory leukocytes during 
acute colitis in lmp7
-/- 
mice (Schmidt et al. 2010). Therefore, it was of interest to examine the 
generation as well as migration patterns of neutrophils in the context of inflammation in lmp7
-
/-
 mice.  
Neutrophils generated in the bone marrow from their myeloid precursors are known to 
accumulate in bone marrow and spleen under physiological conditions. It is thought that these 
organs act as reservoirs for mature neutrophils which can be rapidly deployed to sites of 
inflammation or infection (Kolaczkowska and Kubes 2013). lmp7
-/-
 mice were examined for 
their bone marrow neutrophil homeostasis in the absence of inflammation to evaluate whether 
the lack of LMP7 affects their constant production. The bone marrow neutrophil homeostasis 
in absence of inflammation in lmp7
-/-
 mice was similar to that in the WT bone marrow. The 
bone marrow neutrophil frequencies in both groups were comparable (Fig. 6, A and B). 
Notably, data analysed from the spleens of naïve lmp7
-/-
 mice showed that they harboured 
fewer frequencies of neutrophils as compared to WT neutrophil frequencies (Fig. 6, C and 
D).  
Hence, these results are suggestive that the production of bone marrow neutrophils 
seems to be unaffected by LMP7 deficiency and it is implicative that LMP7 possibly governs 
the blood neutrophils migration into the spleen under physiological steady state. 
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Figure 6. Neutrophil homeostasis in bone marrow and spleens of naïve lmp7
-/-
 mice. (A-D) Cells 
were gated on SSChigh granulocytes and CD11b+ Ly-6G+ neutrophils were analysed by flow cytometry. (A) 
FACS analysis of CD11b+ Ly-6G+ neutrophils subsets in bone marrow from naïve WT and naïve lmp7 -/- mice. 
(B) Bar graph displays mean frequency of CD11b+ Ly-6G+ bone marrow neutrophils. (C) FACS analysis of 
CD11b+ Ly-6G+ neutrophils subsets in the spleen from naïve WT and naïve lmp7 -/- mice. (D) Bar graph 
displays mean frequency of CD11b+ Ly-6G+ splenic neutrophils. Representative dot plots from two independent 
experiments are shown, where n = 6 mice per group. For (B) and (D), data represent mean ± SEM, n.s. = not 
significant , *P<0.05 
 
 
4.7. Highly impaired colonic neutrophil influx upon 
AOM/DSS treatment in lmp7-/- mice 
 
Neutrophil release from the bone marrow increases the number of circulating neutrophils 
which can be recruited into the organs for e.g., colon in response to inflammation. It has been 
shown that neutrophils are involved in the process of carcinogenesis through the release of 
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reactive oxygen species (ROS) and by triggering IL-1/IL-6 pro-tumorigenic axis (Galdiero et 
al. 2013; Sadik, Kim, and Luster 2011; Wang et al. 2014). Thus, to test the potential role for  
A                        
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Figure 7. Colonic neutrophils and macrophages influx upon AOM/DSS treatment in lmp7 
-/- 
mice. Leukocytes were isolated from the colon of naïve and AOM/DSS-treated WT and lmp7 -/- mice on day 30 
after CAC induction. Cells were stained and gated on SSChigh granulocyte gate. (A) Frequency and (B) total cell 
numbers of CD11b+Ly-6G+ neutrophils were analysed by flow cytometry. LPMCs were isolated from the colon 
of naïve and AOM/DSS-treated mice on day 30 after CAC induction. Cells were stained for CD11b and MHC-
II and gated for (C) Cd11b+ MHC-II+ macrophages. For all figures, data represent mean ± SEM, where n = 10-
12 mice per group, *P<0.05, *** P<0.001.   
 
LMP7 in this process, neutrophil influx was assessed in WT and lmp7
-/- 
mice colons upon 
induction of CAC. During chronic colitis phase, the strong influx of neutrophils was observed 
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in the colonic lamina propria (cLP) of WT mice. Discordantly, neutrophil influx in the cLP of 
lmp7
-/- 
mice was heavily impaired (Fig. 7A). Moreover, in the colon of lmp7
-/- 
mice there was 
a severe defect in neutrophils cell numbers (Fig. 7B). Additionally, a moderate defect in 
macrophage cell numbers was also detected after CAC induction (Fig. 7C).  
Thus, these results indicate that the cLP influx of neutrophils is dependent on LMP7 
activity and it is suggestive that LMP7 regulates the neutrophil migration into peripheral 
tissues such as colon during ongoing inflammation. 
 
 
4.8. Reduced neutrophil influx upon during peritonitis in 
lmp7 -/- mice 
 
In order to test if the impaired colonic neutrophil influx in the absence of LMP7, during 
colonic inflammation, might reflect a more general LMP7-mediated phenomenon, the 
frequency of neutrophils was determined during peritonitis. 4 hours after the intraperitoneal 
administration of thioglycollate, peritoneal lavages from WT and LMP7-deficient mice were 
evaluated for neutrophil migration.  
In relation to the WT mice, considerably fewer neutrophils were attracted to the 
peritoneum of lmp7
-/- 
mice as an inflammatory response to thioglycollate injection (Fig. 8, A 
and B). Taken together, these observations imply that LMP7 is one of the key molecular 
coordinators for the recruitment of tumour- and inflammation-promoting neutrophils. 
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Figure 8.  The neutrophil influx during peritonitis in lmp7 
-/- 
mice. (A and B) Peritoneal exudates from 
untreated (A) and thioglycollate-treated mice (B) after 4 hours were stained for CD11b+ Ly-6G+ neutrophils and 
were analysed by flow cytometry. A representative of two experiments is shown where n=6 mice per group. 
 
 
4.9. Significant reduction in chemokine, chemokine 
receptor and cell adhesion molecule expression in 
lmp7-/- mice upon CAC induction 
 
Inflammatory cells and tumours are intimately linked by the enhanced expression of pro-
tumorigenic chemokines such as CXCL1, CXCL2 and CXCL3. Inflammation-associated 
cancers have a complex chemokine network that attracts immune cells such as neutrophils 
directly to the tumour site (Balkwill.F. 2004). Further, cell adhesion molecules which enable 
neutrophils to migrate through the endothelium toward the target tissues are known to be 
upregulated in response to pro-inflammatory cytokines such as TNF- and IL-17A 
(Kolaczkowska and Kubes 2013).  
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Figure 9. Chemokines, chemokine receptor and cell adhesion molecule expression in lmp7
-/-
 
mice during chronic colitis phase. qRT-PCR analyses for expression of chemokines (A) Cxcl1, Cxcl2, 
Cxcl3, chemokine receptors (B) Cxcr1, Cxcr2 and cell adhesion molecule (C) VCAM1 was performed using 
whole colon tissues from naïve and AOM/DSS-treated mice at day 30 after CAC induction. Untreated mice 
were used as negative controls. Data represents mean ± SEM where n =10-12 mice per group. n.d.: not 
detectable, *P<0.05. 
 
We hypothesised that defective profile of pro-inflammatory cytokines and 
chemokines, mostly regulated by the transcription factor NF-B, might be the cause for 
decreased neutrophil influx in the colon lmp7
-/- 
mice. Therefore, gut neutrophil-homing 
chemokines and their receptors along with one of the cell adhesion molecules VCAM-1, 
which plays an important role in neutrophil migration across endothelium, were examined in 
AOM/DSS-treated WT and lmp7
-/- 
mice. 
The mRNA expression of Cxcl1, Cxcl2 and Cxcl3 was significantly upregulated in the 
colons of AOM/DSS-treated WT mice. In contrast, lmp7
-/- 
mice displayed no profound 
upregulation of these chemokines during CAC progression (Fig. 9A). Additionally, at the 
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same time point, the chemokine receptors Cxcr1 and Cxcr2, which are expressed on the 
cellular surface of circulating neutrophils, were also severely downregulated in AOM/DSS-
treated lmp7
-/-
 mice as compared to WT animals (Fig. 9B). Therefore, it seems very likely that 
LMP7 is responsible for the expression of Cxcl1, Cxcl2 and Cxcl3 chemokines and the 
chemokine receptors Cxcr1 and Cxcr2.  Furthermore, VCAM1 expression was conceivably 
enhanced in WT mice post-AOM/DSS treatment, while in LMP7 deficient mice it was almost 
unaltered in comparison to naïve mice (Fig. 9C). Thus, these data highlight the role of LMP7 
in regulating the cell adhesion molecule VCAM1 expression. 
In summary, it seems highly plausible that LMP7 plays a prime role in regulating 
expression of pro-tumorigenic chemokines, chemokine receptors and cell adhesion molecules 
which impacts neutrophil recruitment into the gut amidst inflammation-driven carcinogenesis. 
 
 
4.10. Impairment of VCAM1 mRNA expression by LMP7 
inhibitor ONX-0914   
 
To assess the direct consequence of LMP7 blockade on VCAM1 expression, primary human 
umbilical vascular endothelial cell line (HUVEC) was treated with LMP7-specific inhibitor 
ONX-0914 and expression of this gene was analysed by quantitative RT-PCR.  
HUVECs were stimulated with TNF- that has been shown to act as a stimulus 
required for induction of VCAM1 expression. It was evident that the addition of 
immunoproteasome (iP) -specific inhibitor ONX-0914 could significantly reduce TNF--
mediated VCAM1 expression in HUVECs (Fig. 10). This result strongly implies that LMP7 
plays an important role in induction of VCAM1 expression. This finding is in accordance with 
previous study demonstrating that inhibition of NF-B signalling pathways by an unselective 
proteasome inhibitor MG132 strongly downregulates VCAM1 expression (Allport et al. 
1997).  
Therefore, we conclude that iP-specific inhibitors such as ONX-0914 might be used to 
block NF-B-mediated expression of pro-inflammatory chemokines, cytokines and cell 
adhesion molecules. However, more extensive future studies are needed in order to prove the 
direct impact of LMP7 activity on the expression of these specific genes.   
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Figure 10. Investigation of mRNA expression of VCAM1 in HUVECs after ONX-0914 
treatment. Quantitative real-time PCR analysis for mRNA expression of VCAM1 was performed using 
primary human umbilical vascular endothelial cell line (HUVEC). HUVECs were treated stimulated with 10 
ng/ml of rhTNF-, with or without 250 nM ONX-0914. Two independent experiments were performed. 
**P<0.01 
 
 
4.11. Presence of putative NF-κB binding sites in promoter 
regions of chemokine genes Cxcl1, Cxcl2, Cxcl3 and 
endothelial adhesion molecule VCAM1 
 
It is well documented that the transcription factor NF-B, which is under direct proteasomal 
control, binds to the promoter region of various inflammatory molecules and triggers their 
gene expression. Genes under NF-B regulation have conserved NF-κB binding sequences 
within their promoter and enhancer regions (Jurida et al. 2015). In order to determine if 
neutrophil-homing chemokines Cxcl1, Cxcl2, Cxcl3 along with endothelial adhesion molecule 
VCAM1 possess any NF-κB binding motifs, sequences upstream of their respective 
transcription start site (TSS) of genes were analysed by using AliBaba2 algorithm. It was 
found that there was a NF-κB binding motif „GGGAATTTCCC‟ with a highly conserved 
sequence in the proximity to their respective TSSs in the genes coding for chemokines Cxcl1, 
Cxcl2, Cxcl3 along with gene encoding endothelial adhesion molecule VCAM1. This sequence 
was found in proximal promoter of humans, rats and mice, particularly in the regulatory 
region 100-200 base pairs upstream of TSS (Fig. 11A). Further examination of regions farther 
away from the TSS revealed that there possibly might be even more NF-κB binding motifs 
but with a loss of stringent sequence conservation (Fig. 11B). 
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In conclusion, these data imply that immunoproteasome/NF-κB signalling cascade 
might be responsible for regulation of expression of Cxcl1, Cxcl2 and Cxcl3 along with 
VCAM1 and it may act by directly binding to the promoter of these genes. 
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Figure 11.  Putative NF-B binding sites in promoter regions of chemokine genes Cxcl1, Cxcl2, 
Cxcl3 and endothelial adhesion molecule VCAM1. Genomic regions upstream of transcription start site 
(TSS) of Cxcl1, Cxcl2, Cxcl3 and VCAM1 genes were examined for putative NF-B binding motifs using the 
bioinformatics program AliBaba2 algorithm. (A) The conserved NF-B binding sequence was found in mice, 
rats and humans. (B) Position of all possible NF-B binding sites within approximately 1500 base pairs upstream 
of TSS of Cxcl1, Cxcl2, Cxcl3 and VCAM1 genes in mice, rats and humans. 
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4.12. Foxp3+ Tregs and CD8+ T cells unaffected by 
AOM/DSS treatment in lmp7-/- mice 
 
In most cancers, regulatory T cells (Tregs) are thought to support tumour cells by supressing 
the anti-tumour immunity mediated by cytotoxic CD8
+
 T cells. It has been shown that 
transient depletion of Tregs improves anti-tumour immune responses upon CAC induction 
(Pastille et al. 2014). 
 
   A                                                 B 
                       
Figure 12. Frequencies of Foxp3
+
CD4
+
 Tregs and CD8
+
 T cells after AOM/DSS treatment in 
lmp7
-/- 
mice. (A and B) LPMCs were isolated from the colon of naïve and AOM/DSS-treated mice on day 30 
after CAC induction. Cells were stained for CD3, CD4, CD8 and Foxp3 and gated either for frequency of 
CD3+CD4+Foxp3+Tregs (A) or CD3+CD8+T cells (B). In addition to determining CD8+T cell frequency, the 
total cell numbers for this cell population was also examined (C). For all figures, data represent mean ± SEM 
where n = 10-12 mice per group.. n.s. = not significant. 
 
As a part of the adaptive immune response in the CAC development, Foxp3
+
CD4
+
 
Tregs and CD8
+
 T cell populations were also examined via flow cytometry in WT and lmp7
-/-
 
mice after they were treated with AOM/DSS. During the peak of inflammation, colonic 
Foxp3
+ 
Tregs and CD8
+
 T cell populations observed in lmp7
-/-
 mice were not different from 
those in WT mice. It was found that there was no apparent variation in frequency of the 
colonic lamina propria Foxp3
+ 
Tregs (Fig. 12A) and CD8
+
 T cell population amongst the 
AOM/DSS-treated lmp7
-/-
 or WT mice (Fig. 12B).  
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These results suggest that, in the context of CAC, colonic Foxp3
+ 
Tregs and CD8
+
 T 
cell populations probably do not contribute to observed outcome in lmp7
-/-
 mice after 
AOM/DSS treatment. 
 
 
4.13. IL-17A cytokine production is reduced in lmp7 -/- and 
lmp2 -/- CD4+ T cells  
 
CD4
+ 
T cells secrete cytokines which play a role in the regulation as well as propagation of 
the inflammatory responses associated with development of cancer (Disis 2010). For example, 
in AOM/DSS-induced CAC model, mice lacking IL-17A expression have been shown to 
display significantly reduced tumour numbers as compared to WT animals (Hyun et al. 2012). 
In order to investigate the possible effects of immunoproteasome (iP) -deficiency on 
the adaptive arm of the immune system, CD4
+ 
T cells differentiated under Th0-, Th1-, Th17- 
and Treg-inducing conditions were analysed for their characteristic cytokine expression and 
transcription factor signature in WT and in lmp7
-/-
 mice. lmp2
-/-
 mice were also analysed in 
this experiment along with lmp7
-/-
 mice in order to compare any variations in two iP-deficient 
mice strains. CD4
+
 T cells were isolated from the spleen and lymph nodes of WT, lmp7
-/-
 and 
lmp2
-/-
 mice with the purity above 90 %, cultured for three days and subsequently were 
examined using flow cytometry. After CD4
+
 T cell culture differentiation there were no 
noticeable differences between WT and lmp7
-/-
 Th1 cells but there was a slight increase in 
IFN- production in lmp2-/- Th1 cells (Fig. 13A). Treg frequencies from WT, lmp7-/- and 
lmp2
-/-
 mice analysed by flow cytometry were also found to be similar (Fig. 13B). In contrast, 
the IL-17A production was severely reduced in lmp7
-/-
 and lmp2
-/-
 Th17 cells as compared to 
their WT counterparts (Fig. 13C). 
 It seems very probable that the IL-17A production in Th17 cells is under iP control. 
These data are in agreement with a previously reported study demonstrating that Th17 cells 
lacking LMP7 are not capable of inducing IL-17A production (Kalim et al. 2012). Hence it 
can be postulated that endogenous activity of iPs influences the pro-inflammatory cytokine 
IL-17A production by CD4
+
 T cells.  
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Figure 13. Th1, Th17 and Treg differentiation from lmp7
-/-
 and lmp2
-/-
 derived CD4
+
 T cells. (A-
C) CD4+ T cells were purified from spleens and lymph nodes of WT, lmp7−/− and lmp2-/- mice. Cells were 
cultured for three days under Th1-, Th17-, Treg-inducing conditions or were left unpolarised. Representative 
dot plots show the expression of cytokines IFN- and IL-17A under Th0- and Th1- conditions (A). The 
histograms display percentages of Foxp3 in WT, lmp7−/− and lmp2-/-derived CD4+ Tregs (B). Representative 
dot plots show the expression of cytokines IFN- and IL-17A under Th17 conditions (C). Three similar 
experiments were performed where n=2-3 mice per experiment. 
 
 
4.14. LMP7 inhibition leads to increase in IFN-γ 
expression in CD4+ Th1 cells  
 
After observing that the IFN- production from Th1 cells derived from lmp2-/- mice was 
significantly increased as compared to that from WT Th1 cells, it was of interest to evaluate 
the consequence of LMP7 inhibition on IFN- production from WT Th1 cells.  
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CD4
+
 T cells were isolated from the spleen and lymph nodes of WT mice with the 
purity above 90 % and cultured for three days under Th1-polarising conditions. During the 
differentiation procedure, one group of WT Th1 cells was treated with LMP7-inhibitor ONX-
0914 and the other group was left untreated. These Th1 cells were examined subsequently 
using flow cytometry.  
 
    A                                                            B 
                     
Figure 14. Effect of LMP7- inhibition on IFN- from WT-derived CD4+ Th1 cells. (A-B) CD4+ T 
cells were purified from spleens and lymph nodes of WT mice. Cells were cultured for three days under Th1-
inducing conditions. Representative dot plots show the expression of cytokines IFN- under Th1- conditions 
(A). The graph displays the percentage of IFN--producing WT Th1 cells from the control and the ONX-0914-
treated cells (B). Two similar experiments were performed where n=2-3 mice per experiment; *P<0.05. 
 
In contrast to the untreated WT Th1 cells, the ONX-0914-treated WT Th1 cells 
displayed an increased IFN- production from Th1 cells (Fig. 14, A and B). However, these 
data are in contradiction with a previous study which reported that when LMP7 activity is 
inhibited using ONX-0914 in WT Th1 cells, these cells display a reduced IFN- production 
(Kalim et al. 2012). Based on our observation, we conclude that the IFN- production is 
upregulated under LMP7-inhibitory conditions in Th1 cells. 
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4.15. LMP7 as well as NF-κB inhibition leads to a 
profound decline in IL-17A and IRF-4 expression in 
CD4+ Th17 cells  
 
To investigate in greater detail, how immunoproteasomes might regulate expression of pro-
tumorigenic cytokine IL-17A, Th17 cells were generated and relevant signalling molecules 
were investigated by Western blot and flow cytometric analysis. Recently, MALT1 kinase, a 
component of so-called BMC complex containing BCL-10, CARMA-1 and MALT1, which 
activates NF-B in T cells, has been described to crucially regulate expression of IL-17A 
(Brüstle et al. 2012). 
With the purpose of evaluating the consequence of LMP7 inhibition on processing of 
NF-B subunit p105, Western blot analysis was performed for in vitro WT CD4+ T cell 
cultures treated with and without ONX-0914. Untreated control cell culture samples showed 
degradation of the p105 subunit and activation of this NF-B signalling pathway over a 
period of 1 h which signifies proteolytic processing of NF-B by the proteasome.  
Although, in ONX-0914-treated samples, the p105 subunit was also partially 
degraded, the activation of this signalling cascade began in a delayed manner as it is seen in 
the immunoblot (Fig. 15A). To test the specificity of ONX-0914 effect on blockade of NF-B 
p105 activation, the potential impact on MAPK/ERK pathway was examined by detecting 
phospho-ERK protein levels which are indicative of activated ERK protein. It was found that 
the ERK pathway was unaffected highlighting the selectivity of ONX-0914 for NF-B 
signalling pathway (Fig. 15A).  
To test direct impact of ONX-0914 on IL-17A production, WT CD4
+
 T cell were 
cultured for three days under Th17-inducing conditions with or without this LMP7-specific 
inhibitor. As a control for direct effect of transcription factor NF-B on IL-17A expression, 
the inhibitor BAY 11-7082 of IKK kinase, which is known to activate NF-B directly, was 
used. On day 3 of cell culture, IL-17A production was severely impaired in both NF-B 
inhibitor BAY 11-7082- and LMP7 inhibitor ONX-0914-treated WT CD4
+
 T cells as 
compared to the untreated cells (Fig. 15B).  
Together these data imply that in WT CD4
+
 T cells, processing of NF-B subunit 
p105 is dependent on LMP7 subunit and that LMP7-inhibition significantly delays the p105 
processing and activation of the NF-B pathway in these cells. Additionally, when LMP7 and 
NF-B activity was blocked separately using their respective inhibitors, IL-17A production 
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by Th17 cells was highly decreased in both cases implying that a functional LMP7/NF-B 
axis is important for induction of IL-17A production. 
 
 A                                                            B 
             
 C                                                                               D 
                       
Figure 15. Analysis of IL-17A and IRF-4 expression in CD4
+
 Th17 after NF-B and LMP7 
inhibition. CD4+ T cells were purified from spleens and lymph nodes of WT mice. Cells were cultured 
either under Th17-inducing conditions or were left unpolarised. (A) Analysis of NF- B p105 and ERK 
activation in CD4+ T cells after stimulation with PMA/ionomycin was done for indicated times. One group of 
cells was additionally treated with 400 nM ONX-0914. Two independent experiments were performed where 
n=2 mice per group. (B) Representative FACS dot plots showing IL-17A and IFN- expression in CD4+ T 
cells cultured under Th17 conditions for three days in the presence of inhibitors BAY 11-7082 and ONX-
0914, respectively. Three independent experiments were performed where n=2 mice per group. (C) 
Immunoblot analysis of IRF4 expression in Th17 cells cultured for 16 h in the presence of either 200 or 400 
nM ONX-0914. (D) Th17 cells were cultured for three days with or without 400 nM BAY 11-7082 or 400 
nM ONX-0914 and subsequently intracellular staining for IRF4 was performed. Three independent 
experiments were performed, where n = 2 mice per group. 
 
Since IL-17A production is known to be dependent on transcription factor IRF4 
(Brüstle et al. 2007) and NF-B has been shown to induce IRF4 expression in T and B cells 
(Jacque et al. 2014), the protein level of IRF4 was assessed in a similar experimental setup. 
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Western blot analysis was performed with WT CD4
+
 cell cultures under Th17 polarising 
conditions. 
 It was found that the expression of IRF4 was partially inhibited under the influence of 
varying doses of ONX-0194. As expected, unstimulated CD4
+
 T cells did not express IRF4. 
After 16 h of cell cultures, IRF4 protein expression was lower in ONX-0914-treated cells as 
compared to the untreated samples (Fig. 15C). To verify this data, WT Th17 cells were 
cultured for three days and flow cytometry for BAY 11-7082- and ONX-0914-treated samples 
was performed. Intracellular staining (ICS) for IRF4 revealed the expression of this 
transcription factor was highly diminished in both inhibitor-treated samples as compared to 
the IRF4 expression in untreated Th17 cells (Fig. 15D).  
Data from these experiments strongly advocate for LMP7 as one of the key regulators 
for the optimal expression and activity of not only NF-B but also of IRF4 in Th17 cells 
which are the main cellular source of IL-17A during the induction of CAC. 
Previously, it was published that ONX-0914 inhibited IFN- production under Th1-
inducing conditions (Kalim et al. 2012). Remarkably, we observed a slightly increase of IFN-
 expression upon ONX-0914 but not after BAY 11-7082 treatment of Th17 cells. Similarly, 
lmp7
-/-
 Th1 cells did not show reduced IFN- production (Fig. 15B), which contradicts the 
previously published data. To test, if ONX-0914 is able to modulate IFN- expression in our 
experimental setup, Th1 cells were cultured for three days in the presence of absence of this 
LMP7 inhibitor. Interestingly, instead of detecting reduced IFN- levels, an enhanced IFN- 
expression was observed in ONX-0914-treated Th1 cells (Fig. 14). 
 
 
4.16. LMP7 blockade inhibits acute and chronic colitis  
 
The specific LPM7 inhibition by ONX-0914 has been demonstrated to attenuate inflammation 
in experimental model of colitis and arthritis (Muchamuel et al. 2009; Basler et al. 2010). We 
speculate that the pharmacological blockade of immunoproteasomes might act as potential 
anti-inflammatory therapy for dampening inflammation-driven carcinogenesis. 
During the course of acute colitis or chronic colitis phase upon CAC induction, LMP7 
activity was blocked by LMP7-specific inhibitor ONX-0914 to investigate its ramification on 
ongoing inflammation and subsequently on the outcome of CAC. It was observed that LMP7 
inhibition reduced inflammation as well as inflammation-driven carcinogenesis in the colon. 
74 
 
In acute model of colitis, advancement of DSS-induced inflammation was blocked by 
ONX-0914 in WT mice, which is in accordance with previously published data (Basler et al. 
2010) . WT mice that were not treated with ONX-0914 showed a significant colon length 
reduction on day 8 after oral administration of DSS caused due to colon edema. On the 
contrary, no significant differences were observed in colon length between day 0 and day 8 
for ONX-0914-treated WT mice (Fig. 16A).  
           A 
 
           B                                                              C 
 
                                   
Figure 16. Impact of specific LMP7 inhibition of colon inflammation. LMP7-specific inhibitor ONX-
0914 was applied to WT mice during acute and chronic colitis. (A) Colon length of DSS-treated WT mice with 
or without ONX-0914 (6 mg/kg mice, i.p. administration daily) was measured at day 8 after colitis induction by 
2.5 % DSS (n=6 mice per group). Data represent mean ± SEM and are representative of two independent 
experiments.  (B and C) Cytokine secretion for TNF- (B) IL-17A (C) by colon ex vivo explants of AOM/DSS 
treated WT mice in the presence or absence of ONX-0914 (6 mg/kg mice, i.p. administration daily) was 
measured by ELISA at day 30 after CAC induction. Results represent mean ± SEM and are representative of 
two independent experiments, where n=6 mice per group. 
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Advancement of chronic colitis phase in AOM/DSS-treated WT mice was also 
blocked by ONX-0914. On day 30 after CAC induction, pro-inflammatory cytokines IL-17A 
and TNF- measured using ELISA from ex vivo colon explants were considerably reduced in 
the inhibitor-treated group as compared to untreated WT controls (Fig. 16, B and C). Thus, 
ONX-0914 applied during colitis induction successfully confined ongoing inflammation. 
 
 
4.17. LMP7 inhibition abrogates colitis-associated 
carcinogenesis 
 
Based on our observation that LMP7-inhibition during chronic colitis restricted the expression 
of pro-inflammatory cytokines IL-17A and TNF-, our next aim was to inhibit LMP7 during 
the full course of CAC (Fig. 17A).We speculated that the pharmacological blockade of 
immunoproteasomes might act as potential anti-inflammatory therapy for dampening 
inflammation-driven carcinogenesis.  ONX-0914 application to WT mice during three rounds 
of DSS treatment upon CAC induction arrested the progression of carcinogenesis, in stark 
contrast to mice which did not receive the inhibitor.  
HE staining performed on day 80 revealed that the WT mice treated with the LMP7 
inhibitor did not develop any tumours (Fig. 17B). Slides for both inhibitor-treated and -
untreated groups were scored for adenocarcinoma blindly by two pathologists. 
AOM/DSS/inhibitor-treated group scored very low in comparison to the AOM/DSS-treated 
group (Fig. 17C).  
Therefore, it can be concluded that inhibition of LMP7 during CAC arrests 
inflammation and development of inflammation-driven carcinogenesis. This novel finding 
strongly suggest that in vivo application of immunoproteasome-specific inhibitors might be 
useful for treatment of cancers associated with chronic inflammation in patients with 
ulcerative colitis. 
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Figure 17. Effect of specific blockade of LMP7 on the development of CAC.  (A) Experimental 
course of CAC induction in WT mice was performed using 8 mg/kg AOM and 3 cycles of 2.5 % DSS. Mice 
were treated with 6 mg/kg ONX-0914 three times per week starting at day 5 after AOM administration. (B) 
Representative images of HE-stained colon sections of naïve and AOM/DSS-treated WT mice injected with 
ONX-0914 as described in (A). Histology analysis was performed at day 80 after CAC induction. Scale bar: 
100µm. (D) Colonic tumour score on day 80 after CAC induction in naïve and AOM/DSS-treated WT mice 
with or without ONX-0914 administration. Data represent mean ± SEM and are representative of two 
independent experiments, where n =10-12 mice per group, n.d.: not detectable, ***P<0.001.  
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5. Discussion  
 
 
5.1. Lack of LMP7 prevents progression of full scale of 
colitis-associated carcinogenesis (CAC) 
 
5.1.1. LMP7 is essential for the formation of immunoproteasome 
complex during inflammation  
 
The progressive upregulation of the immunoproteasome (iP) subunit LMP7 observed in the 
Western blots from the colons of WT animals exposed to DSS suggests a role of this 
proteasomal immunosubunit in promoting colonic inflammation. This result is in agreement 
with observations of increased LMP7 levels in DSS-induced mice in a previous study (Basler 
et al. 2010) and further supported by the observation of increased expression of LMP7 in the 
inflamed mucosa of IBD patients (Visekruna et al. 2006). This clear increase in LMP7 protein 
expression in response to colonic inflammation, is likely due to the upregulation of pro-
inflammatory cytokines such as IFN-andTNF-  
The reduced protein expression of a majority of the proteosomal structural subunits in 
the colons of inflamed LMP7-deficient mice suggests that the presence of LMP7 is essential 
for the formation of mature iPs in the colon during acute colitis. Our results agree with a 
previous study which demonstrates a significant reduction in the amounts of 20S proteasome 
subunits following Listeria monocytogenes infection in LMP7-deficient mice (Joeris et al. 
2012), which signifies that the incorporation of LMP7 is an essential step in the assembly of a 
functional iP. The increased expression of LMP7 during inflammation may indicate a possible 
involvement of pro-inflammatory cytokines, such as IFN- (Seifert et al. 2010; Heink et al. 
2005) or increased protein synthesis via mTORC1 pathway (Yun et al. 2016), both of which 
have been previously implicated in the induction of iPs. 
Our Western blot analyses also suggest that LMP7 plays a central role in the assembly 
of a functional iP through the recruitment of other proteasomal subunits, such as the structural 
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subunits and the remaining catalytic immunosubunits, which require LMP7 to be integrated 
into the nascent iPs. These results further confirm the findings of another study which shows 
that the incorporation of LMP7 is one of the rate limiting factors during iP assembly (Fricke 
et al. 2007). 
 Our experiments also show that LMP7-deficient mice are characterised by an 
increased accumulation of POMP, which is indicative of the absence of mature iPs. POMP is 
a protein essential for proteasome maturation and is also the first substrate to be degraded by a 
fully mature and functional proteasome (Fricke et al. 2007). Previously, it was shown that 
POMP transiently binds to mature LMP7 and that degradation of POMP signals the 
completion of proteasome assembly (Heink et al. 2005). Our results confirm that there is 
functional interdependency between POMP and LMP7 and that, in the absence of LMP7, 
there is a lack of active iP complex which can degrade POMP. Therefore, it can be concluded 
that LMP7-deficient mice cannot assemble a fully functional and mature iP during colonic 
inflammation. 
 
5.1.2. Lack of functional immunoproteasome in the absence of 
LMP7 protects mice from CAC 
 
The extent of weight loss in LMP7-deficient mice upon CAC induction, coupled with the 
decrease in tumour incidence, implies that LMP7 activity contributes to the severity of the 
CAC. During CAC induction, mice lacking LMP7 were relatively healthy, which is in 
agreement with previous studies, which have demonstrated that, during colitis, LMP7-
deficient mice lost significantly lesser body weight as compared to the WT mice (Schmidt et 
al. 2010; Basler et al. 2010). The presence of observed small tumours in the colons of the 
LMP7-deficient animals after CAC induction indicates that the tumorigenesis may not have 
occurred to a full extent, further underscoring the contribution of LMP7 to the process of 
inflammation-driven carcinogenesis. We therefore conclude that LMP7 is crucially involved 
in development of CAC.  
The presence of an intact gut epithelial layer observed after HE staining in LMP7-
deficient mice, demonstrates lack of epithelial injury due to DSS treatment and no subsequent 
excessive intestinal epithelial cell (IEC) proliferation. Our results further suggest that, even 
after repeated exposure to DSS and administration of the carcinogen AOM, the lack of LMP7 
prevents colonic IECs from undergoing transformation. This finding is supported by the 
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observation that, in LMP7-deficient IECs, the cellular and nuclear morphology are not 
substantially different from those of normal IECs in control mice. These observations clearly 
indicate that, even at a microscopic level, the LMP7-deficient mice do not show any signs of 
carcinogenesis and collectively imply that LMP7 activity during ongoing colonic 
inflammation contributes to IEC transformation.  
Moreover, microscopic examination of PAS-stained colonic sections from LMP7-
deficient mice reveal sufficient mucous production covering the entire epithelial lining, 
suggesting LMP7-deficient mice are protected from DSS injury. These results also support 
our observations of an intact gut epithelium with HE staining. The presence of an intact 
epithelium with a protective mucous layer in LMP7-deficient mice would prevent the 
underlying immune cells from chronic exposure to luminal antigens and, hence, from 
developing chronic inflammation as a result of DSS treatment. 
The normal localisation of cytoplasmic-catenin in the IECs of LMP7-deficient mice 
suggests a lack of tumorigenesis upon CAC induction. Although strong diffuse cytoplasmic 
and nuclear signals were observed for WT mice, colons from LMP7-deficient animals did not 
display a prominent -catenin nuclear signal, which could be due to several possible reasons. 
It has been reported that -catenin accumulates in the nucleus due to the loss-of-function 
mutation of the APC gene in up to 80% of CRCs (Sánchez-tilló et al. 2011), suggesting that 
not all cases of CRCs display nuclear accumulation of -catenin. However, we have not 
determined if the APC gene has been mutated in our study. Another possibility for the lack of 
active nuclear -catenin signal in LMP7 deficient mice could be that its nuclear translocation 
depends on various cross-talks between cellular pathways that might involve 
immunoproteasome activity and can influence the Wnt/-catenin pathway within tumour 
cells. Finally, other techniques, such as nuclear and cytoplasmic protein extraction from 
tumour cells or detection of -catenin via immunofluorescence, should be applied for a more 
specific localisation of -catenin in the AOM/DSS-treated WT colon sections.  
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5.2. LMP7 is a crucial regulator of inflammation during 
the progression of CAC 
 
5.2.1. LMP7 regulates NF-B signalling pathway-mediated 
production of pro-inflammatory cytokines 
 
The downregulation of expression of NF-B subunits p65, c-Rel, and p105/50 at protein level 
during tumorigenesis in AOM/DSS-treated LMP7-deficient mice suggests that NF-B activity 
is dependent on LMP7. In inflammatory bowel disease (IBD) patients, it has been previously 
shown that, NF-κB activation is mediated via LMP7 and that LMP7 is highly abundant in the 
inflamed colon of these patients (Visekruna et al. 2006). It has also been demonstrated that, 
during acute colitis, LMP7-deficient mice exhibit reduced activation of NF-κB (Schmidt et al. 
2010). Furthermore, deletion of a regulatory protein of NF-B, IKK in both epithelial and 
myeloid cells has been shown to reduce the tumour load in the colon upon CAC induction. In 
the same study, it was demonstrated that, in the absence of IKK the epithelial cells exhibit 
increased apoptosis upon CAC induction, since epithelial cell-IKKdeletion prevents 
expression of anti-apoptotic factor Bcl-XL (Greten et al. 2004). These results further 
underscore the crucial role of NF-B in the development of inflammation-driven 
tumorigenesis in the colon. 
When we measured protein expression of proinflammatory cytokines, we observed 
that LMP7-deficient mice cannot mount an inflammatory response in the colon following 
DSS exposure. Previous studies have demonstrated that DSS-treated LMP7-deficient mice 
exhibit reduced expression of pro-inflammatory cytokines, which are mostly regulated by NF-
B signalling pathway (Schmidt et al. 2010; Basler et al. 2010).  
We demonstrated that, despite the chronic DSS exposure, LMP7-deficient mice could 
not produce sufficient colonic IL-6, which suggests a link between reduced IL-6 expression 
and lack of tumorigenesis in these mice. This observation is in accordance to a previous study 
that has shown that ablation of IL-6 reduces colonic tumour progression and invasiveness. It 
was also shown in the same study that IEC-specific deletion of STAT3, a major pro-
tumorigenic IL-6 effector molecule resulted in decrease of the tumour load, which further 
supports the link between IL-6 and tumorigenesis (Grivennikov et al. 2009).  
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We also observed that another pro-inflammatory cytokine TNF- which is partially 
under regulation of NF- is insufficiently produced during CAC development in the colons 
of LMP7-deficient mice. TNF- has been shown to be a crucial mediator which contributes to 
colonic tumorigenesis. In a recent study, it was shown that blocking TNF-with the inhibitor 
etanercept reduces the tumour load in mice upon CAC induction. This study also highlighted 
that there is a reduced tumour incidence in TNF-receptor 1 (TNFR1) deficient mice upon 
CAC induction due to reduced F- activation (Popivanova et al. 2008). Another study 
supportive of our finding, demonstrates a strong correlation of TNF-F- axis, 
specifically in epithelial cells during the progression of CAC. This study showed that TNF-
receptor 2 (TNFR2) was preferentially upregulated in the regenerating IECs during 
inflammation and that specific activation of F-in IECs was TNFR2-dependent in DSS-
treated mice (Onizawa et al. 2009). We, therefore, hypothesise that lack of TNF-expression 
in LMP7 deficient mice is one of the crucial factors preventing tumorigenesis, despite the 
inflammatory stress caused by DSS on epithelial cells. 
A close relationship between IL-17A and CAC has been widely accepted (Moseley et 
al. 2003; Gaffen 2009; Korn et al. 2009). Our observation of restricted tumorigenesis and 
reduced colonic secretion of IL-17A in LMP7-deficient mice is in accordance with various 
recent studies. One such study, utilising a mouse model of CAC with loss of APC function, 
demonstrated that expression of IL-23 and its downstream target cytokine IL-17A increases 
during colon carcinogenesis, thereby underscoring the significance of IL-23/IL-17A axis in 
CAC. The converse was also shown to be true wherein ll23
-/-
 and il17ra
 -/- 
displayed reduced 
tumour multiplicity and proliferation indicating that IL-17A supports a pro-inflammatory as 
well as pro-tumorigenic environment for tumour formation (S. I. Grivennikov et al. 2012). 
Similar observations were reported in studies where it was demonstrated that IL-17A or IL-
17RA ablation reduced colonic inflammation, colonic cellular proliferation and decreased the 
subsequent tumorigenesis. Interplay between IL-17RA and IL-6 was also highlighted by 
findings that demonstrate that IL-17RA ablation reduces IL-6 expression (Hyun et al. 2012; 
Wang et al. 2014). Based on our observation that LMP7-deficient mice produce less IL-17A 
in the colon during chronic inflammation, it is clear that IL-17A production is dependent on 
the LMP7 activity in the colon. Hence, reduced expression of IL-17A in LMP7-deficient mice 
decreases the pro-tumorigenic effect of this cytokine in the colon so that the promotion of 
carcinogenesis does not occur.  
Furthermore, we report that in DSS-treated rag1 
-/- 
lmp7 
-/- 
mice, the IL-17A 
expression at protein level is significantly reduced as compared to the DSS-treated rag1 
-/- 
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mice. In addition to Th17 cells, which are the major source of IL-17A (Weaver et al. 2007), 
innate cells also contribute to the pool of IL-17A. In a study with rag1 
-/- 
mice, it was shown 
that the IL-23/IL-17A axis in innate cells is a crucial signalling cascade, which contributes to 
intestinal pathology during Helicobater hepaticus-mediated colitis (Buonocore et al. 2010). In 
the same study, it was also observed that IL-23-stimulated colonic leukocytes induced IL-17A 
production exclusively from innate lymphoid cells (ILCs). In a similar study, it was observed 
that the cells are the main source of IL-17A in mice lacking Th17 cells, and that innate 
source of IL-17A was sufficient to promote tumorigenesis (Housseau et al. 2016). These two 
studies underscore the role of IL-17A cytokine in carcinogenesis, irrespective of its cellular 
source and also highlights the redundancy of Th17-derived or innate cells-derived IL-17A. 
Our study supports and extends these observations by showing that DSS-treated rag1 
-/-
 mice, 
which lack adaptive immune cells, are able to produce IL-17A. Furthermore, the inability of 
rag1 
-/- 
lmp7 
-/- 
to secrete IL-17A in our study further strengthens the role of LMP7 in IL-17A 
production by innate cells. 
 
5.2.2. LMP7 regulates the influx of pro-tumorigenic leukocytes in 
the colonic lamina propria (cLP) during CAC induction  
 
In the absence of inflammation, LMP7-deficient mice generate bone marrow-derived 
neutrophil granulocytes similarly to the WT, but they accumulate fewer splenic neutrophils.  
This implies that LMP7 has only a selective function in the neutrophil migration into 
peripheral tissues. Our finding indicates that the generation, maturation and egress of 
neutrophil from the bone marrow into the bloodstream are not influenced by the function of 
LMP7. 
The impaired neutrophil influx in the colons of LMP7-deficient mice during chronic 
colitis reflects the role of LMP7 in neutrophil migration in the colon. It has been recently 
reported in two studies that tumour infiltrating neutrophils (TANs) promote CAC. One of 
these studies also demonstrated that tumorigenesis was significantly reduced in mice 
administered with a neutrophil-blocking anti-Ly6G antibody (Shang et al. 2012; Wang et al. 
2014). Our findings support the pro-tumorigenic role of neutrophils in the context of CAC. In 
LMP7-deficient mice, reduced levels of pro-inflammatory cytokines, such as IL-17A, are 
insufficient to attract TANs efficiently as indicated by colonic neutrophil numbers. The role 
of LMP7 in promoting neutrophil migration in the peripheral tissues is further supported by 
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the reduced influx of neutrophils in the peritoneum of LMP7-deficient mice that we observe 
upon thioglycollate induction. It is also known from previous studies that peritoneal 
neutrophil influx upon thioglycollate induction occurs even in the absence of pro-
inflammatory cytokines (Murphy et al. 2010), implying that LMP7 might also controls other 
neutrophil-attracting factors, such as chemokines.  
Furthermore, the slight reduction in macrophage cell number that we observe in the 
colonic lamina propria (cLP) of LMP7-deficient mice implies a role of LMP7 in macrophage 
influx. However, we have not determined the various factors which could have influenced the 
function of colonic macrophages in our study. Future studies could include examination of 
macrophage polarisation factors, such as the cytokines TGF-1 or IL-1and thechemokines 
CCL8 or CXCL9, which would determine whether the detected macrophage population is 
pro-tumorigenic or not. 
Our results show a significant downregulation of the mRNA expression of relevant 
neutrophil-homing chemokines namely, CXCL1-3 and their receptors CXCR1-2 in the 
absence of LMP7 in AOM/DSS-treated mice. These observations are in agreement with those 
of a previously reported microarray analysis of LMP7-deficient mice during acute colitis 
(Schmidt et al. 2010). The downregulation of these factors in the LMP7-deficient mice could 
be due to their reduced expression by colonic epithelial, stromal and inflammatory cells and 
subsequent impairment of neutrophil influx in the colon. These findings collectively imply 
that LMP7 activity plays a central role in regulating the expression of the pro-tumorigenic 
chemokines CXCL1-3 and their receptors CXCR1-2.  
Previous studies demonstrated that the cell adhesion molecule VCAM-1, whose 
induction is TNF--dependent, is an additional factor controlling the transmigration of 
neutrophils (Landskron et al. 2014; Baud and Karin 2001). Interestingly, we observed that 
LMP7-deficient mice that lack TNF- fail to show an induction of VCAM-1 mRNA 
expression, which appears to affect neutrophil transmigration. In addition to these in vivo 
results, our hypothesis that LMP7 activity is required for induction of VCAM-1 is further 
strengthened by our in vitro observations in HUVECs, where the addition of LMP7-specific 
inhibitor ONX-0914 directly inhibits VCAM-1 expression in the presence of TNF-. These 
findings are in accordance with an older study which reported a downregulation of VCAM-1 
expression in HUVECs when treated with MG132, a non-selective 20S proteasome inhibitor 
(Allport et al. 1997; Read et al. 1995). We conclude that LMP7 is one of the factors, which 
governs VCAM-1 expression in an inflammatory environment. Collectively, CXCL1-3, 
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CXCR1-2 and VCAM-1 promote the influx of TANs into the cLP, and in order to achieve 
this, LMP7 activity is indispensable. 
A recent study has linked the upregulation of CXCL1-3 expression with induction of 
NF-B p65 subunit, after IL-1addition (Jurida et al. 2015). The study demonstrates the 
presence of p65 binding sites upstream of the transcriptional start sites (TSSs) of chemokine 
genes IL-8 and CXCL1-3. In agreement with this report, we show that in mice, rats and 
humans, chemokines genes CXCL1-3 possess a conserved NF-κB binding sequence 
„GGGAATTTCCC‟ in their respective TSSs. In our study, the presence of these binding 
sequences is suggestive of the interaction of NF-B with the chemokines gene promoters that 
could be regulating the expression of chemokines directly. Further promoter studies are 
required to confirm the binding of active NF-B dimers on the promoter regions of CXCL1-3 
and VCAM1. Moreover, the link between NF-B and neutrophil-homing factors may be 
further investigated by the potential suppression of CXCL1-3 and VCAM1 gene expression by 
the use of NF-κB inhibitors in cancer cell lines, such HeLa or HT-29. 
Unaltered percentages of Foxp3
+ 
Tregs in WT and LMP2/7 deficient mice, both in 
vivo and in vitro, suggest that the Foxp3 expression in colonic Tregs is not dependent on 
LMP7 activity. However, a previous study reported, that both under in vitro and in vivo 
conditions, LMP7 inhibition promotes Foxp3
+ 
Tregs differentiation via phosphorylation of 
SMAD2/3, proteins which are known to promote expansion of Tregs (Kalim et al. 2012; 
Bollrath and Powrie 2013; Bos and Rudensky 2012). This discrepancy can be explained based 
on a few possible reasons. First, the stable expression of Foxp3
+ 
Tregs in WT and 
immunoproteasome-deficient mice could be related to the differences in profiles of short 
chain fatty acids (SCFAs) produced by gut microbiota. This influence of gut microbiota 
composition and SCFAs profile on mucosal Foxp3
+ 
Tregs induction levels has been 
previously shown  (Brucklacher-Waldert et al. 2014). Second, the expression of Foxp3
+ 
Tregs 
could also be dependent on the activation of some transcription factors, such as PPAR, which 
are induced by dietary antigens, which have been previously shown to convert Th17 to Tregs 
(Klotz et al. 2009). Finally, it is known that TGF-signalling initiates the generation of Th17 
cells as well as Tregs. The Treg developmental pathway is abrogated in the presence of TGF-
β plus IL-6 or IL-21, promoting Th17 cell differentiation (Ueno et al. 2015). Therefore, it 
would be pertinent to study the Th17-Treg dynamics in the context of LMP7 and CAC in a 
greater detail. 
The normal frequency and absolute cell numbers of CD8
+
 T cells that we observe in 
LMP7-deficient mice suggests that the anti-tumour immunity provided by the cytotoxic CD8
+
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T cells is functional, despite the absence of LMP7. A previous study has demonstrated that the 
profile of tumour antigens generated varies between tumour cells and that the profile is 
dependent on the subtypes of proteasomes in the cell (Coulie et al. 2014). A very recent study 
has highlighted that CD8 T
+ 
cell antigen selection under physiological conditions is dictated 
not only by the immunosubunits 1i, 2i and5i, but also by a specialised thymoproteasome 
subunit5t (Kincaid et al. 2016). Although our study shows that, in the absence of LMP7, the 
detected CD8
+
 T cells seem to be normal and LMP7-deficient mice do not develop tumours, it 
would still be relevant in future studies to explore the colonic epithelial cell-specific antigens 
generated by the LMP7-deficient iPs during CAC induction. Using high throughput 
sequencing, a more detailed analysis of the repertoire of antigens generated by LMP7-
deficient CD8
+
 T cells during CAC would give us an insight into how these mice are able to 
maintain cytotoxic CD8
+
 T cell activity.  
 
5.2.3. LMP7 plays a central role in the production of pro-
tumorigenic cytokine IL-17A in the colon during CAC 
induction  
 
The slight increase in IFN-production in LMP2- and LMP7-derived Th1 cells suggests that 
immunoproteasomes (iP) might regulate the effector function of Th1 cells in vitro. The 
observed increase in IFN-secretion in Th1 cells under the influence of ONX-0914, is further 
suggestive of the potential role of LMP7 in downregulating the effector function of Th1 cells 
as well. These results are contrary to those of a previous study, which state that LMP7 
inhibition with ONX-0914 reduces IFN-secretion from Th1 cells. The authors hypothesise 
that this effect is due to reduced STAT1 phosphorylation, which is known to be an important 
factor for Th1 differentiation (Kalim et al. 2012). In our study, further analyses are required to 
account for a slight increase of IFN-secretion from Th1 cells. The expression of the crucial 
Th1 lineage-specific transcription factor T-bet, which is known to drive Th1 differentiation , 
can be evaluated in future experiments. Phosphorylation of other transcription factors such as 
STAT1 and STAT4, known to act upstream of T-bet, can also be evaluated in LMP7-
deficiency and -inhibitory conditions. Presence of alterations in IL-12 receptor expression can 
also be checked as IL-12 is the key cytokine, which drives Th1 differentiation. Changes in 
any of these factors, individually or in combination, could also lead to the overall rise in IFN-
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 production from cells where the iP function is inhibited. The overall expression levels of 
LMP7, specifically in Th1 subset, can also be evaluated as this will serve to understand how 
LMP7 functions under Th1-polarising conditions. Lastly, determining the IFN- production 
from intestinal Th1 cells during CAC induction, under LMP7-inhibitory conditions, could 
help to also substantiate our findings.  
The reduction in IL-17A production from Th17 cells from LMP2- and LMP7-deficient 
mice in our in vitro experiments indicates that iPs play an intrinsic role in controlling IL-17A 
expression. These results support our in vivo data and are in accordance with a previous 
study, demonstrating that IL-17A production is decreased significantly in the supernatants of 
colonic explants of LMP7-deficient mice during inflammation (Schmidt et al. 2010). The 
reduction in colonic IL-17A production in LMP7-deficient mice is possibly owed to the 
reduced migration of immune cells, such as neutrophils that are also able to produce IL-17A, 
which leads to an overall reduction in IL-17A levels. However, our study with LMP7-
deficient Th17 cells implies that, apart from the reduced colonic immune cells migration, the 
lack of LMP7 influences the inherent capacity of Th17 cells to produce IL-17A, which in turn 
impairs it‟s effector functions. More studies are needed to determine if the master 
transcription factor ROR-t is altered in Th17 cells devoid of iPs or after iP inhibition. 
Furthermore, it would be of interest to examine if other essential factors STAT3, TGF- and 
IL-23 influencing Th17 differentiation, expansion and maintenance during CAC induction are 
under direct LMP7 regulation. It would also be important to examine the expression level of 
LMP7 specifically in the Th17 subset and correlate it with our findings. 
Our finding that LMP7-inhibition delays the degradation of NF-B subunit p105 
supports our results from in vivo experiments, which also show reduced NF-B protein levels 
in the colons of LMP7-deficient mice during CAC. In order to analyse the consequence of 
LMP7 and NF-B inhibition on IL-17A production, we individually inhibited these two 
proteins in Th17 cells, which in both cases led to reduced IL-17A production. This confirms 
our hypothesis that IL-17A production in Th17 cells requires a functional LMP7/NF-B/IL-
17A axis.  
Previous studies have shown that the NF-B regulator MALT-dependent cleavage of 
RelB is an important factor in making the Th17 cells pathogenic, and that IRF4 is an essential 
transcription factor for Th17 differentiation (Brüstle et al. 2007; Mudter et al. 2008; Brüstle et 
al. 2012) In this study, we extend this finding by demonstrating that LMP7, via NF-B 
activity, is required for the optimal activity of IRF4. Another study has also reported that NF-
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B precursor protein p105 is required for IRF4 expression in B lymphocytes (Jacque et al. 
2014). Therefore, the decreased IRF4 expression in Th17 cells lacking LMP7 may be due to 
defective NF-B activity, which we also observed in in vivo studies with LMP7-deficient 
mice. It has also been shown that IRF4 binds to the promoter region of IL-17A and directly 
regulates its production in Th17 cells (Mudter et al. 2011). Thus, we hypothesised that IRF4 
expression might be influenced by lowered LMP7-dependent NF-B function; this was 
confirmed when we observed that, when LMP7 was inhibited in Th17 cells, the IRF4 protein 
expression was also lowered accordingly. It would be of interest to further examine the IRF4 
activity in LMP7 deficient Th17 cells by overexpressing IRF4 and to determine if this restores 
the IL-17A cytokine production. As it is already known that IRF4-deficient mice are protected 
from T cell-mediated transfer colitis (Mudter et al. 2008), it would be relevant to also examine 
the yet unexplored role of IRF4 in the context of LMP7-deficiency during CAC. Taken 
together, our findings reveal that the defect in IL-17A secretion by the Th17 cells lacking 
LMP7 is probably due to the dysregulated signalling cascade of LMP7/NF-B/IRF4.   
 
 
5.3. Inhibiting LMP7 activity is a potential therapeutic tool 
which can block inflammation-associated 
carcinogenesis 
 
5.3.1. Inhibition of LMP7 suppresses inflammation during acute 
and chronic colitis  
 
The attenuation of colonic inflammation due to LMP7-inhibition with ONX-0914 during 
acute and chronic colitis further supports our in vivo observations of LMP7-mediated 
regulation of pro-inflammatory mediators in mice devoid of LMP7. Our findings are in 
accordance with a previous study, which demonstrated that administration of ONX-0914 
exhibits reduced inflammation during acute colitis, as indicated by a normal colon length and 
decreased pro-inflammatory cytokine expression (Basler et al. 2010). We have previously 
reported that the use of Bortezomib, a non-selective proteasome inhibitor, confined 
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inflammation during acute colitis in WT mice (Schmidt et al. 2010). In the current study, the 
normal length of the colon after DSS/ONX-0914 treatment indicates lack of colonic 
inflammation and oedema, and therefore, signifies the function of LMP7 in the advancement 
of inflammation. Inhibiting LMP7 activity attenuates chronic colonic inflammation as 
indicated by the reduction in TNF-and IL-17A levels during chronic colitis phase. These 
findings also corroborate our hypothesis that LMP7 is one of the key regulators of 
inflammation in the colon. Our observations from the use of LMP7-specific inhibitor also 
reinforce our current hypothesis that iP-mediated-NF-B activation regulates the expression 
of various pro-inflammatory cytokines during inflammation.  
 
5.3.2. Inhibition of LMP7 restricts inflammation-driven 
tumorigenesis in the colon 
 
Absence of colonic tumours upon the administration of ONX-0914 clearly demonstrates the 
role of immunosubunit LMP7 in the development of tumorigenesis. The observed effect of 
significantly reduced pro-inflammatory and pro-tumorigenic cytokine levels due to blocked 
LMP7 activity results in the suppression of inflammation-dependent carcinogenesis. Our 
hypothesis is further supported by the microscopic analysis of colon tissues of the 
AOM/DSS/ONX-0914 treated mice, which indicates almost complete absence of any 
transformed or hyper-proliferative IECs. 
Our study also suggests that the specific inhibition of LMP7 might be a better 
therapeutic option for CAC, as this inhibitor works efficiently at a relatively low dose when 
compared to other non-selective and more toxic proteasome inhibitors (Kisselev and 
Groettrup 2014). Moreover, ONX-0914 has been already used to attenuate the progression of 
experimental arthritis by blocking cytokine production in mice (Muchamuel et al. 2009). 
Although the effect of ONX-0914 is ultimately the inhibition of NF-B, which is similar to 
the effect of other non-selective proteasome inhibitors, the selectivity of this particular 
inhibitor ensures that it does not affect the housekeeping function of constitutive proteasomes 
in cells. Another advantage of using this inhibitor is that by inhibiting the NF-B signaling 
pathway, it subsequently targets those genes which are under NF-B regulation in immune 
cells, including pro-tumorigenic cytokines, chemokines and adhesion molecules. Therefore, 
rather than targeting individual pro-tumorigenic factors, it would probably be more effective 
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to manipulate the function of a master regulator of inflammation and carcinogenesis, such as 
NF-B, by blocking LMP7 activity.  
 
 
5.4. Final discussion  
 
The results reported in this study demonstrate that the assembly and maturation of 
immunoproteasome (iP) complex requires the presence of the immunosubunit LMP7 during 
colon inflammation. The absence of the LMP7 subunit leads reduced abundance of all 20S 
proteasomal subunits. As the LMP7-deficient cells contain immature iP complex, the 
degradation of their target proteins is affected. Thus, in the absence of LMP7, the proteasome-
mediated degradation of IB inhibitors and subsequent activation of transcription factor NF-
B is lowered due to the lack of functional iPs and reduced proteasome quantity during 
inflammation.  
During CAC induction and in the constant presence of DSS, WT IECs are damaged 
and the epithelial barrier is breached and leads to TLR activation, which in turn activates 
important proinflammatory signalling cascades such as NF-B pathway. The hyperactivation 
of NF-B in epithelial and immune cells may trigger activation of anti-apoptotic factor and 
genes involved in cell cycle progression, such as Bcl-2 and Cyclin-D, which promote 
excessive proliferation and survival of IECs after CAC induction. Impaired expression of NF-
B subunits such as p65, c-Rel and p105/50 in the LMP7-deficient mice implies a reduced 
NF-B activity during induction and progression of CAC in these animals. The end result of 
this decreased NF-B activity is that the AOM/DSS-treated LMP7-deficient mice are 
protected from developing tumours in the colon.  
The synergistic action and interplay of pro-inflammatory and pro-tumorigenic 
cytokines, such as IL-6, TNF- and IL-17A, via STAT3 and NF- regulation, drives the 
generation of a tumorigenic environment in WT mice (Fig.7). In the inflamed colon, 
continuous secretion of IL-6 and IL-17 is suggestive of perpetual infiltration of immune cells 
which directly act on transformed intestinal epithelial cells (IECs). Because LMP7-deficient 
mice do not display any signs of inflammation, we hypothesise that the colons in these mice 
lack a pro-inflammatory microenvironment, which is normally needed to promote tumour 
development upon CAC induction. Additionally, complete absence of TNF-in AOM/DSS-
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treated colons of LMP7-deficient mice is one of crucial reasons protecting these mice from 
CAC. This is because TNF- acts directly on the IECs to augment their oncogenic signalling 
pathways. It can further support carcinogenesis by inducing IL-6 expression in a NF-B-
dependent manner. Furthermore, decreased IL-6 levels in LMP7-deficient mice also imply 
that the reduced pro-proliferative and anti-apoptotic effects of this cytokine do not allow for 
any uncontrolled IEC transformation. Finally, reduced IL-17A production in LMP7-deficient 
mice and absence of IL-17A in rag1 
-/- 
lmp7 
-/-
 mice implies that LMP7 is a key regulator in 
controlling IL-17A production not only in Th17 cells but also in innate immune cells. The 
role of LMP7 in controlling IL-17A production in innate cells is a significant finding but is 
yet unexplored. Future studies with AOM/DSS-treated rag1 
-/- 
lmp7 
-/-
 mice are needed to 
evaluate the mechanism by which LMP7 mediates IL-17A production from the innate cells. 
The regulation of IL-17A in Th17 cells seems to be via LMP7/NF-B/IRF4 signalling 
cascade. The contribution of this axis in IL-17A production was confirmed by decrease in IL-
17A cytokine levels observed in Th17 cells when LMP7 and NF-B were individually 
inhibited. Future studies are needed to examine the role of LMP7 in regulation of production 
of other pro-tumorigenic cytokines. 
We postulate that LMP7 is a key immunological factor, which regulates inflammation-
dependent processes, leading to recruitment of immune cells, such as TANs which promote 
tumorigenesis by producing cytokines and reactive oxygen species causing DNA damage 
(Fig.7). The lack of LMP7 results in insufficient levels of neutrophil-homing factors, such as 
chemokines CXCL1-3, and their receptors CXCR1-2. Additionally, the expression of VCAM-
1 is likely reduced due to the absence of TNF- in LMP7-deficient mice, since TNF- is a 
well-known inducer of endothelial cell adhesion molecules. The down-regulation of VCAM-1 
expression by the LMP7-inhibitor ONX-0914 in HUVECs further supports a direct role of 
LMP7 in controlling the transcription of cell-adhesion molecules. Furthermore, NF-B, a 
transcription factor dependent on proteasomal activity, seems to bind directly to the gene 
promoters of neutrophil-homing chemokines and cell adhesion molecules. Therefore, the 
reduced chemokine and chemokine receptor expression in LMP7-deficient mice can be 
interpreted as the consequence of insufficient NF- activation. Future studies should be 
performed to verify the role of LMP7 in neutrophil migration by evaluating neutrophil influx 
under the influence of ONX-0914 during CAC induction. 
Administration of the LMP7-specific inhibitor ONX-0914 in WT mice during CAC 
also leads to restricted carcinogenesis, the phenotype which was also observed in LMP7-
deficient mice after CAC induction. These results further underscore the significance of 
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LMP7 in promoting CAC. Histological evidence from our study supports the hypothesis that 
ONX-0914-treated mice have an intact epithelial barrier. Furthermore, reduced pro-
inflammatory cytokine levels imply the absence of an inflammatory environment in the colon, 
which contributes to the suppression of progression of tumorigenesis. It would be of interest 
to analyse if the expression of various other pro-tumorigenic factors in WT mice after ONX-
0914 treatment is reduced. 
 
 
 
Figure 7. Role of LMP7 during colitis-associated carcinogenesis. Upon CAC induction, inflammation-
induced upregulation of immunoproteasome (iP) leads to excessive NF-B activation. This results in increased 
production pro-tumorigenic cytokines (IL-17A, IL-6 and TNF-), chemokines (CXCL1-3) and cell-adhesion 
molecules (VCAM-1) which are under NF-B regulation. These pro-tumorigenic factors initiate tumorigenesis 
by recruiting tumorigenic leukocytes, such as tumour-associated neutrophils (TANs) which transmigrate through 
the endothelium, as well as the expansion of Th17 cells. TANs support tumorigenesis by producing reactive 
oxygen species (ROS) which cause DNA damage and Th17 cells secrete IL-17A cytokine which further attracts 
TANs. The LMP7/NF-B/IRF4 axis further controls the IL-17A production which attracts more TANs. The 
consequence of the synergistic action of all the pro-tumorigenic factors leads to the initiation and the promotion 
of intestinal epithelial cells (IECs) hyper-proliferation, which ultimately leads to tumorigenesis. Blocking of the 
iP subunit LMP7 with a specific inhibitor, ONX-0914, blocks colonic inflammation and subsequent 
carcinogenesis, thus making LMP7 a valuable therapeutic target in CAC. 
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Taken together, the absence of LMP7 blocks pro-inflammatory and pro-tumorigenic 
immunological factors, and thereby protects the mice from developing CAC. This novel 
finding qualifies LMP7 to be a therapeutic target with the administration of LMP7-specific 
inhibitor ONX-0914 in IBD patients with ongoing colonic tumorigenesis. However, more 
studies are required to understand the role of LMP7 in spontaneous colon carcinogenesis, 
which occurs in the absence of inflammation. Such a study can further highlight the 
therapeutic value of LMP7 even in cases of inflammation-independent CRC. 
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7. Abbreviations  
ACF Abberant crypt foci 
AOM Azoxymethane 
BSA Bovine serum albumin 
CAC Colitis-associated carcinogenesis 
CCL- Chemokine (C-C motif) ligand 
CD Crohn‟s disease 
CLRs C-type lectin receptors 
COX-2 Cyclooxygenase-2  
CRC Colorectal cancer 
CXCL- Chemokine (C-X-C motif) ligand 
CXCR- Chemokine (C-X-C motif) receptor 
cDNA Complementary DNA 
cLP Colonic lamina propria 
cP Constitutive proteasome  
DC Dendritic cell  
DMSO Dimethylsulfoxide 
DRiPs Defective ribosomal products 
DSS Dextran sodium sulphate 
EAE Experimental autoimmune encephalomyelitis 
EDTA Ethlyene diamine tetra acetic acid 
EGF Epidermal growth factor 
EMT Epithelial-mesenchymal transition 
ER Endoplasmic reticulum  
e.g. for example 
FACS Fluorescence activated cell sorting  
FCS Fetal calf serum 
Foxp3 Fork head protein 3  
Fig. Figure 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GMCSF Granulocyte colony stimulating factor 
GRO Growth-regulated oncogene 
g gram  
104 
 
HE Haematoxylin and eosin stain 
HPRT hypoxanthine-guanine phosphoribosyl transferase 
HUVEC Human umbilical vascular endothelial cells 
h hour 
IBD Inflammatory bowel disease  
ICAM-1 Intercellular adhesion molecule 1 
ICS Intracellular staining  
IEC Intestinal epithelial cells  
IEL Intraepithelial lymphocytes 
IFN- Interferon gamma 
IL - Interleukin- 
ILCs Innate lymphoid cells 
Il17-ra IL-17 receptor A 
IB Inhibitor of kappa B 
IKK IB kinase  
iNOS Inducible nitric oxide synthase 
IRF4 Interferon regulatory factor 4  
i.p. intaperitonially  
iP Immunoproteasome 
JAK Janus Kinases 
kDa kilodalton 
LMP- Low molecular weight polypeptide 
LPMC Lamina propria mononuclear cells 
MALT-1 Mucosa-associated lymphoid tissue 1 
MECL-1 Multicatalytic endopeptidase complex  
MHC class I Major histocompatibility complex class I  
MMPs Matrix metalloproteases 
mTORC-1 mechanistic target of rapamycin 1  
mA milliampere  
mRNA Messenger ribonucleic acid 
mins minutes 
mM millimolar  
ml millilitre 
µg  microgram 
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µg/ml  microgram per millilitre 
µl  microlitre 
µm  micrometre 
µM  micromolar 
µg  microgram 
NaCl Sodium chloride  
NF-B Nuclear Factor kappa B 
NLRs NOD-like receptors 
ng nanogram 
ng/ml nanogram per millilitre 
NH4Cl Ammonium chloride 
PAGE Polyacrylamide gel electrophoresis 
PAS Periodic-Schiff staining  
PBS Phosphate-buffered saline  
PCR Polymerase chain reaction 
PIs Proteasome inhibitors  
POMP Proteasome maturation protein 
PVDF  Polyvinylidenfluoride 
rag1 recombination activating gene 1 
RNA Ribonucleic acid  
RNS Reactive nitrogen species 
ROS  Reactive oxygen species 
ROR-t Retinoic orphan receptor - t 
rpm Revolutions per minute  
SDS  sodiumdodecylsulfate 
SCFA Short chain fatty acids 
SPF Specific pathogen free 
STAT- Signal transducer and activator of transcription- 
TANs Tumour-associated neutrophils  
TAMs Tumour-associated macrophages 
TFF3 Treofil factor-3 
TGF- Transforming growth factor- 
TLRs Toll-like receptors 
TNF- Tumour necrosis factor-   
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TREMs Triggering receptors expressed on myeloid cells 
Th T helper cells  
Treg Regulatory T cells 
UBA Ubiquitin-associated domains 
UBL Ubiquitin-like 
UC Ulcerative colitis 
UPS Ubiquitin-proteasome system 
VCAM-1 Vascular endothelial adhesion molecule-1 
VGEF Vascular growth endothelial factor  
WT Wild type 
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